CN104744460B - β‑咔啉,二氢‑β‑咔啉和四氢‑β‑咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用 - Google Patents

β‑咔啉,二氢‑β‑咔啉和四氢‑β‑咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用 Download PDF

Info

Publication number
CN104744460B
CN104744460B CN201310752240.2A CN201310752240A CN104744460B CN 104744460 B CN104744460 B CN 104744460B CN 201310752240 A CN201310752240 A CN 201310752240A CN 104744460 B CN104744460 B CN 104744460B
Authority
CN
China
Prior art keywords
methyl
indole
carboxylic acid
tetrahydropyrido
acid hydrazide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310752240.2A
Other languages
English (en)
Other versions
CN104744460A (zh
Inventor
汪清民
宋红健
刘永贤
刘玉秀
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nankai University
Original Assignee
Nankai University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nankai University filed Critical Nankai University
Priority to CN201310752240.2A priority Critical patent/CN104744460B/zh
Priority to EP14876613.2A priority patent/EP3091015B1/en
Priority to EP18203967.7A priority patent/EP3459951B1/en
Priority to PCT/CN2014/094847 priority patent/WO2015101206A1/zh
Priority to EP18203964.4A priority patent/EP3459950B1/en
Priority to US15/109,371 priority patent/US10208033B2/en
Publication of CN104744460A publication Critical patent/CN104744460A/zh
Application granted granted Critical
Publication of CN104744460B publication Critical patent/CN104744460B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/10Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof
    • A01N47/12Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof containing a —O—CO—N< group, or a thio analogue thereof, neither directly attached to a ring nor the nitrogen atom being a member of a heterocyclic ring
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/10Carbamic acid derivatives, i.e. containing the group —O—CO—N<; Thio analogues thereof
    • A01N47/22O-Aryl or S-Aryl esters thereof

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dentistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明涉及β‑咔啉,二氢‑β‑咔啉和四氢‑β‑咔啉生物碱衍生物(I)及其制备方法和在防治植物病毒、杀虫、杀菌方面的应用,式中各基团的意义见说明书。本发明的β‑咔啉,二氢‑β‑咔啉和四氢‑β‑咔啉生物碱衍生物表现出特别优异的抗植物病毒活性,还具有杀菌活性和杀虫活性。

Description

β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物及其制备 方法和在防治植物病毒、杀菌、杀虫方面的应用
技术领域
本发明涉及β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用,属农药技术领域。
背景技术
β-咔啉,二氢-β-咔啉和四氢-β-咔啉的骨架结构广泛存在于天然产物和药物分子中。Harmine和四氢Harmine分属于β-咔啉和四氢β-咔啉生物碱,它们是骆驼蓬生物碱(harmala alkaloids)的代表性化合物。Harmine最早是从骆驼蓬(P.harmala L.)中分离得到的,该生物碱对白血病细胞株HL60和K562表现出细胞毒性。四氢Harmine是从金虎尾科植物Banisteriopsis caapi中分离到的具有荧光的分子,该化合物对五羟色胺的再摄取具有弱的抑制作用。Harmaline是中枢神经系统的激动剂和单胺氧化酶(MAO-A)可逆的抑制剂。
目前,对于β-咔啉,二氢-β-咔啉和四氢-β-咔啉及其类似物的研究主要集中在抗肿瘤,杀人体寄生虫和单胺氧化酶抑制剂方面的研究。但是,据我们所知,对于β-咔啉,二氢-β-咔啉和四氢-β-咔啉及其类似物的抗植物病毒活性没有文献报道,其杀菌活性和杀虫活性的报道较少。在杀菌活性方面:2007年甘肃农业大学的符海波等研究了骆驼蓬在不同溶剂中的提取液对番茄灰霉菌、黄瓜枯萎菌、番茄早疫菌、黄瓜黑星菌等4种病原菌的孢子萌发均有一定的抑制作用,其EC50分别为0.060、0.199、0.105、0.223g/mL(符海波,丁德芳,赵红梅,杨顺义,草原与草坪,2008,1,44-48.);2007年复旦大学的闻韧等报道了具有1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉结构的衍生,并对该类衍生物进行了体外抗稻瘟霉菌活性的研究(CNl01020688);2011年华南农业大学的张耀谋等报道了具有β-咔啉-3-肟酯结构的化合物,同时研究了该类化合物对香蕉炭疽、芒果炭疽和番茄晚疫的抑菌活性(卢少莹,张耀谋,合成化学,2011,19(6),769-772.);2012年该课题组又报道了具有1-对三氟甲基苯基-β-咔啉-3-羰基双酰肼结构的化合物,但是,化合物数量较少且仅测试了对水稻纹枯菌的抑菌活性(蔡瑛,黄剑锋,张美丹,曾勇,张耀谋,合成化学,2012,20(6),736-739.)。在杀虫活性方面:2005年北京农学院的赵晓萌等报道了骆驼蓬生长期地上部分的乙醇提取物,氯仿提取物及水提取物对桃蚜、月季长管蚜和朱砂叶螨的触杀活性,结果是在10mg/mL的浓度下对叶螨的触杀活性均在95%以上,在10mg/mL的浓度下对两种蚜虫触杀活性在70%以上(赵晓萌,曾召海,中国农学通报,2005,21(4),278-279.);2010年华南农业大学的钟国华等报道了1,3-二取代的β-咔啉和四氢-β-咔啉衍生对尖音库蚊幼虫和萝卜蚜的杀虫活性,其中,具有1-苯基取代的β-咔啉和四氢-β-咔啉-3-甲酯结构的化合物对尖音库蚊幼虫的LC50分别为20.82mg/L和23.98mg/L,对萝卜蚜的LC50分别为53.16mg/L和68.05mg/L(Zeng,Y.;Zhang,Y.M.;Weng,Q.F.;Hu,M.Y.;Zhong G.H.Molecules2010,15,7775-7791.)。
发明内容
本发明的目的是提供β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用。本专利的β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物表现出很好的抗植物病毒活性,还具有杀菌活性和杀虫活性。
本发明的β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物是具有如下通式(I)所示结构的化合物:
本发明所述的β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物(I)是具有如下四种通式(Ia,Ib,Ic,Id)所示结构的化合物:
本发明的β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物(I)还包括如下所示结构的天然化合物:
本发明的二氢-β-咔啉生物碱可以按如下方法制备(路线一):首先在吲哚3-位引入醛基得到化合物1,1再与硝基甲烷和乙酸铵反应得到中间体2,经过一步还原得到色胺3,然后再经过酰化和环化得到二氢-β-咔啉生物碱Harmalan。
路线一:
本发明的β-咔啉和四氢-β-咔啉生物碱可以按如下方法制备(路线二):首先色胺3在硫酸的催化条件下与乙醛水溶液反应得四氢-β-咔啉生物碱Tetrahydroharmane,然后该化合物经过一步脱氢氧化得β-咔啉生物碱Harmane。
路线二:
本发明的四氢-β-咔啉生物碱可以按如下方法制备(路线三):首先Harmine与苄溴反应得季铵盐4,然后经过还原得化合物5,最后经钯炭催化氢化得四氢-β-咔啉生物碱Tetrahydroharmine。
路线三:
本发明的β-咔啉生物碱可以按如下方法制备(路线四):Harmine酸性条件下脱甲基得β-咔啉生物碱Harmol。
路线四:
本发明的β-咔啉生物碱衍生物(Ia)可以按如下方法制备(路线五):Harmane在酸性条件下与溴代琥珀酰亚胺反应得化合物Ia-1和Ia-2,酸性条件下与硝酸钠反应得苯环上硝基取代的化合物Ia-3和Ia-4。
路线五:
本发明的β-咔啉生物碱衍生物(I)可以按如下方法制备(路线六):Harmol与异氰酸酯反应得化合物Ia-5,Harmol与酰氯反应得化合物Ia-6-Ia-8。Harmol在缩合剂的作用下与氨基酸反应得化合物Ia-9。
路线六:
本发明的β-咔啉和四氢-β-咔啉生物碱衍生物(Ia和Ib)可以按如下方法制备(路线七):首先,L-色氨酸与乙醛水溶液反应得环化产物Ib-1,然后经过一步酯化得化合物Ib-13。化合物Ib-13经过脱氢氧化得化合物Ia-10。化合物Ia-10碱性条件下水解得化合物Ia-11,化合物Ia-10经过四氢铝锂还原得化合物Ia-12,该化合物经过氧化得醛Ia-13。化合物Ia-13与丙二酸反应得丙烯酸Ia-14,用同样的路线可以合成化合物Ia-15-1a-16。
路线七:
本发明的四氢-β-咔啉生物碱衍生物(Ib)可以按如下方法制备(路线八):L/D-色氨酸在酸性或碱性条件下与脂肪醛或芳香醛经过Pictet-spengler反应得到酸Ib-1-Ib-6,然后再经过酯化得到酯Ib-7-Ib-12。
路线八:
本发明的二氢-β-咔啉生物碱衍生物(Ib)可以按如下方法制备(路线九):L-色氨酸与乙醇反应得乙酯6,6经过酰化后再与三氯氧磷反应得二氢-β-咔啉生物碱衍生物Ib-14。
路线九:
本发明的四氢-β-咔啉生物碱衍生物(Ib)可以按如下方法制备(路线十):甲酯Ib-7与水合肼(80%)反应得化合物Ib-15,化合物Ib-7与胺反应得到酰胺Ib-16和Ib-18。
路线十:
本发明的四氢-β-咔啉生物碱衍生物(Ib)可以按如下方法制备(路线十一):酸Ib-1在缩合试剂的作用下与胺反应得酰胺Ib-17,Ib-19-Ib-20。
路线十一:
本发明的四氢-β-咔啉生物碱衍生物(Ic)可以按如下方法制备(路线十二):酰肼化合物Ib-15与脂肪醛或芳香醛反应得到相应的酰腙类化合物Ic-1-Ic-29。
路线十二:
本发明的四氢-β-咔啉生物碱衍生物(Id)可以按如下方法制备(路线十三):酰肼化合物Ib-15与酰氯反应得到相应的双酰肼类化合物Id-1-Id-7。
路线十三:
以上各通式中,
R代表氢、一个至四个卤素原子、一个至四个硝基、一个至四个氰基、一个至四个1-6碳烷氧基、一个至四个羟基、一个至四个酯基、一个至两个OCH2O、一个至两个OCH2CH2O、一个至四个0-10碳胺基、一个至四个1-6碳烷羰基、一个至四个1-10碳烷氧羰基、一个至四个1-10碳烷胺羰基、一个至四个1-6碳烷氧羰氧基、一个至四个1-6碳烷胺羰氧基、一个至四个1-10碳α-胺基烷羰氧基;
R1分别代表氢、羟基、卤素原子、氰基、酯基、酰胺基、1-10碳烃基、1-6碳烷氧基、1-4碳烷基羰氧基、1-4碳烷氧基羰氧基、1-10碳含氮杂环、1-10碳含氧杂环、1-10碳含硫杂环,以及上述化合物的立体异构体;
R2分别代表氢、羟基、1-6碳烷氧基、氨基、1-10碳胺基、卤素原子、氰基、醛基、1-6碳烷羰基、1-10碳烷氧羰基、1-10碳烷胺羰基、1-6碳烷氧羰氧基、1-6碳烷胺羰氧基;
X分别代表氢、氧、硫、氮、碳;
R3分别代表氢、羟基、卤素原子、氰基、酯基、酰胺基、1-10碳烃基、1-6碳烷氧基、1-4碳烷基羰氧基、1-4碳烷氧基羰氧基、1-10碳含氮杂环、1-10碳含氧杂环、1-10碳含硫杂环;
R4和R5分别代表氢、1-10碳烃基、1-10碳含氮杂环、1-10碳含氧杂环、1-10碳含硫杂环;R4和R5为1-10碳脂肪环、1-10碳不饱和碳环、1-10碳含氮杂环、1-10碳含氧杂环、1-10碳含硫杂环;
R6分别代表氢、羟基、氨基、1-10碳烃基、1-6碳烷氧基、1-10碳胺基、取代苯环、1-10碳含氮杂环、1-10碳含氧杂环、1-10碳含硫杂环。
本发明所述的β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物(I)优选如下化合物:
(E)-3-(1-甲基-吡啶并[3,4-b]吲哚-3)-丙烯酸(Ia-14);
(E)-3-(1-(噻吩-2)-吡啶并[3,4-b]吲哚-3)-丙烯酸(Ia-15);
(E)-3-(1-(吡啶-3)-吡啶并[3,4-b]吲哚-3)丙烯酸(Ia-16);
(1S,3S)-N-丁基-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-16);
(1S,3S)-N-环己基-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-17);
(1S,3S)-N-(2-羟乙基)-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-18);
(1S,3S)-N-(二甲氨基甲基)-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-19);
(1S,3S)-N-((四氢呋喃-2)-甲基)-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-20);
(1S,3S)-N′-苯亚甲基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-1);
(1S,3S)-N’-(4-叔丁基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-2);
(1S,3S)-N’-(4-二甲氨基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-3);
(1S,3S)-N’-(4-硝基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-4);
(1S,3S)-N’-(4-氯苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-5);
(1S,3S)-N’-(2,4-二氯苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-6);
(1S,3S)-N’-(3,4-二氯苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-7);
(1S,3S)-N’-(4-甲氧基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-8);
(1S,3S)-N’-(3-甲氧基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-9);
(1S,3S)-N’-(2-甲氧基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-10);
(1S,3S)-N’-(3,4-二甲氧基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-11);
(1S,3S)-N’-((苯并[d][1,3]二氧亚甲基-5)-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-12);
(1S,3S)-N’-((2,3-二氢苯并[b][1,4]二氧芑-6-亚甲基)-1-甲基)-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-13);
(1S,3S)-N’-(6-羟基萘-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-14);
(1S,3S)-N’-(吡啶-4-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-15);
(1S,3S)-N’-(吡啶-3-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-16);
(1S,3S)-N’-(吡啶-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-17);
(1S,3S)-N’-(呋喃-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-18);
(1S,3S)-N’-(吡咯-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-19);
(1S,3S)-N’-(噻吩-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-20);
(1S,3S)-N’-(咪唑-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-21);
(1S,3S)-N’-((E)-丁-2-烯亚基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-22);
(1S,3S)-N’-亚丁基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-23);
(1S,3S)-N’-亚辛基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-24);
(1S,3S)-N’-(环己基亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-25);
(1S,3S)-N’-(2,2-二甲基亚丙基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-26);
(1S,3S)-N′-(1-苯基亚乙基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-27);
(1S,3S)-N′-(3,3-二甲基丁-2-亚基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-28);
(1S,3S)-N′-亚环己基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-29);
N′-((1S,3S)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-三甲酸基)苯并[d][1,2,3]噻二唑-7-甲酰肼(Id-1);
4-甲基-N′-((1S,3S)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰基)-1,2,3-噻二唑-5-甲酰肼(Id-2);
(1S,3S)-N′-异烟酰基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-3);
(1S,3S)-N′-苯甲酰基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-4);
(1S,3S)-N′-正己酰基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-5);
(1S,3S)-N′-特戊酰基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-6);
(1S,3S)-N′-(环戊基甲酰基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-7)。
本发明通式(I)的化合物具有优异的抗植物病毒活性,能很好地抑制烟草花叶病毒、辣椒病毒、水稻病毒、番茄病毒、甘薯病毒、马铃薯病毒和瓜类病毒及玉米矮花叶病毒等,可有效防治烟草、辣椒、水稻、番茄、瓜菜、粮食、蔬菜、豆类等多种作物的病毒病,尤其适合于防治烟草花叶病。通式(I)的β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物表现出很高的离体抗TMV活性,而且还表现出很好的抗烟草花叶病毒(TMV)活体活性,部分β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物的抗烟草花叶病毒活体活性明显优于商品化品种病毒唑,尤其是化合物Harmalan,Tetrahydroharmane,Harmane,Tetrahydroharmine,Ia-1,Ib-8,Ib-13,Ib-15,Ic-1-Ic-9,Ic-12,Ic-19,Ic-20,Ic-24-Ic-26,Ic-28,Id-1,Id-6,Id-7在100μg/mL浓度下抗烟草花叶病毒活性与商品化品种宁南霉素在100μg/mL浓度下的活性相当。据我们所知,这也是首次报道β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱及其衍生物具有抗植物病毒活性。
本发明通式(I)的化合物作为植物病毒抑制剂可以直接使用,也可以加上农业上接受的载体使用,也可以和其他抗植物病毒剂如苯并噻二唑(BTH)、噻酰菌胺(TDL)、4-甲基-1,2,3-噻二唑-5-甲酸(TDLA)、DL-β-氨基丁酸(BABA)、病毒唑、宁南霉素、菲并吲哚里西啶生物碱安托芬、联三唑类化合物XY-13和XY-30、病毒A、水杨酸、多羟基双萘醛、氨基寡糖素形成互作组合物使用,这些组合物有的表现增效作用,有的表现相加作用。
本发明通式(I)的化合物具有杀粘虫、棉铃虫和玉米螟及尖音库蚊活性。
本发明通式(I)的化合物对以下14种病原菌表现出杀菌活性,这14种病原菌:黄瓜枯萎、花生褐斑、苹果轮纹、番茄早疫、小麦赤霉、马铃薯晚疫、油菜菌核、黄瓜灰霉、水稻纹枯、辣椒疫霉、水稻恶苗、小麦纹枯、玉米小斑和西瓜炭疽。
本发明通式(I)的化合物作为杀虫杀菌剂可以直接使用,也可以加上农业上接受的载体使用,也可以和其他杀虫杀螨杀菌剂如吡螨胺、溴虫腈、乙螨唑、唑螨酯等组合使用,这些组合物有的表现增效作用,有的表现相加作用。
具体实施方式
下述的实施例和生测试验结果可用来进一步说明本发明,但不意味着限制本发明。
实施例1:二氢-β-咔啉生物碱Harmalan的合成
吲哚-3-甲醛的合成
500mL单口瓶中加入DMF140mL,0℃下加入27mLPOCl3,然后加入25g(214mmol)吲哚的50mL DMF溶液,搅拌过夜。依次加入50mL水,150mL20%的氢氧化钠水溶液,加热回流6h。将反应液倒入水中,抽滤,得棕色固体20.6g。收率66%,熔点190-192℃(文献值:190-192℃);1H NMR(400MHz,CDCl3)δ10.08(s,1H,CHO),8.80(s,1H,NH),8.32-8.34(m,1H,Ar-H),7.86(d,4JHH=2.8Hz,1H,Ar-H),7.44-7.62(m,1H,Ar-H),7.31-7.36(m,2H,Ar-H)。
(E)-3-(硝基乙烯基)吲哚的合成
500mL单口瓶中加入吲哚-3-甲醛20g(138mmol),乙酸铵5.3g(69mmol),硝基甲烷200mL,加热回流8h。加入200mL水和150mL乙酸乙酯,分液。有机相用水洗,干燥,减压蒸出溶剂。用二氯甲烷进行常压柱层析得黄色固体19.1g。收率74%,熔点170-171℃;1HNMR(400MHz,CDCl3)δ8.74(s,1H,NH),8.30(d,3JHH=13.6Hz,1H,CH),7.79-7.83(m,2H,CH andAr-H),7.69(d,4JHH=2.8Hz,1H,Ar-H),7.48-7.50(m,1H,Ar-H),7.33-7.38(m,2H,Ar-H)。
色胺的合成
1000mL单口瓶中加入500mL四氢呋喃,加入11.4g(300mmol)四氢铝锂和9.4g(50mmol)(E)-3-(硝基乙烯基)吲哚。加热回流7h。水淬灭未反应完全的四氢铝锂。抽滤,滤液脱溶,加入乙酸乙酯和水分液。有机相用饱和食盐水洗,无水硫酸钠干燥,脱溶,得红色粘稠物,放置固化,得棕色固体8.9g。收率89%,熔点115-117℃;1H NMR(400MHz,CDCl3)δ8.26(s,1H,NH),7.62(d,3JHH=7.6Hz,1H,Ar-H),7.36(d,3JHH=8.0Hz,1H,Ar-H),7.20(t,3JHH=7.6Hz,1H,Ar-H),7.12(t,3JHH=7.6Hz,1H,Ar-H),7.02(s,1H,Ar-H),3.04(t,3JHH=6.4Hz,2H,CH2),2.91(t,3JHH=6.8Hz,2H,CH2),1.47(s,2H,NH2)。
Harmalan的合成
100mL单口瓶中加入色胺0.5g(3.13mmol),40mL二氯甲烷,2mL三乙胺。加入0.27g(3.44mmol)乙酰氯的5mL二氯甲烷溶液,室温反应5h。反应液用饱和碳酸氢钠水溶液洗,无水硫酸钠干燥,脱溶。不需提纯,加入20mL甲苯和20mL氯仿,3mL三氯氧磷。加热回流7h。加碳酸钠调反应液至碱性。用二氯甲烷萃取反应液,饱和食盐水洗有机相,无水硫酸钠干燥,脱溶。用二氯甲烷/甲醇(10∶1)进行常压柱层析得棕黄色固体0.35g。收率60%,熔点110-113℃;1H NMR(400MHz,CDCl3)δ9.47(s,1H,NH),7.60(d,3JHH=8.0Hz,1H,Ar-H),7.48(d,3JHH=8.4Hz,1H,Ar-H),7.31(t,3JHH=8.0Hz,1H,Ar-H),7.16(t,3JHH=8.0Hz,1H,Ar-H),3.88(t,3JHH=8.4Hz,2H,CH2),2.95(t,3JHH=8.8Hz,2H,CH2),2.53(s,3H,CH3);HRMS(ESI)calcd forC12H13N2(M+H)+185.1073,found185.1077。
实施例2:Tetrahydroharmane和Harmane的合成。
Tetrahydroharmane的合成
500mL单口瓶中加入40%乙醛水溶液8.1mL(43.75mmol),水250mL,浓硫酸5滴。室温搅拌0.5h,加入色胺3.50g(21.88mmol),加热回流7h。加氢氧化钠调pH=10左右,加入二氯甲烷萃取,有机相用饱和食盐水洗,无水硫酸钠干燥,脱溶,用二氯甲烷/甲醇(5∶1)进行常压柱层析得棕色固体2.53g。收率62%,熔点173-175℃;1H NMR(400MHz,d6-DMSO)δ10.68(s,1H,NH),7.35(d,3JHH=8.0Hz,1H,Ar-H),7.27(d,3JHH=8.0Hz,1H,Ar-H),6.98-7.02(m,1H,Ar-H),6.91-6.95(m,1H,Ar-H),3.99-4.04(m,1H,CHNH),3.33(s,1H,CHNH),3.14-3.19(m,1H,CH2NH),2.81-2.87(m,1H,CH2NH),2.51-2.62(m,2H,CH2CH2),1.36(d,3JHH=6.8Hz,3H,CH3CH);HRMS(ESI)calcd for C12H15N2(M+H)+187.1230,found187.1231。
Harmane的合成
250mL单口瓶中加入0.85g(4.57mmol)四氢咔啉,0.53g(4.57nmol)马来酸,120mL水和0.85g Pd/C。加热回流8h。抽滤,水洗。滤液用氢氧化钠调pH=9-10,有大量白色固体产生。抽滤得白色固体0.5g。收率60%,熔点244-245℃;1HNMR(400MHz,CDCl3)δ8.41(s,1H,NH),8.37(d,3JHH=5.2Hz,1H,Ar-H),8.12(d,3JHH=8.0Hz,1H,Ar-H),7.83(d,3JHH=5.2Hz,1H,Ar-H),7.52-7.57(m,2H,Ar-H),7.26-7.32(m,1H,Ar-H),2.84(s,3H,CH3);HRMS(ESI)calcd for C12H11N2(M+H)+183.0917,found183.0915。
实施例3:Tetrahydroharmine的合成
季铵盐的合成
250mL单口瓶中加入Harmine0.5g(2.36mmol),乙酸乙酯120mL,苄溴0.48g(2.83mmol)。加热回流12h。抽滤,得浅黄色固体0.67g,收率74%,熔点>300℃;1H NMR(400MHz,d6-DMSO)δ12.78(s,1H,NH),8.74(d,3JHH=6.4Hz,1H,Ar-H),8.58(d,3JHH=6.8Hz,1H,Ar-H),8.37(d,3JHH=8.8Hz,1H,Ar-H),7.35-7.44(m,3H,Ar-H),7.23(d,3JHH=7.2Hz,2H,Ar-H),7.12(d,4JHH=1.0Hz,1H,Ar-H),7.08(dd,3JHH=8.8Hz,4JHH=1.0Hz,1H,Ar-H),5.98(s,2H,CH2),3.95(s,3H,OCH3),2.98(s,3H,CH3)。
N-苄基Tetrahydroharmine的合成
250mL单口瓶中加入季铵盐0.67g(1.75mmol),甲醇150mL,加入0.53g(14.0mmol)硼氢化钠的30mL甲醇溶液。加热回流15h。脱溶,加入二氯甲烷和水,分液。有机相用饱和食盐水洗,无水硫酸钠干燥,脱溶,用二氯甲烷/甲醇(20∶1)进行常压柱层析得棕色固体0.47g,收率88%。收率88%,熔点147-149℃;1H NMR(400MHz,CDCl3)δ7.68(s,1H,NH),7.50-7.52(m,2H,Ar-H),7.43-7.47(m,3H,Ar-H),7.36-7.40(m,1H,Ar-H),6.90(dd,3JHH=8.8Hz,4JHH=2.4Hz,1H,Ar-H),6.83(d,4JHH=2.4Hz,1H,Ar-H),3.97(d,2JHH=13.6Hz,1H,CH2C6H5),3.81(q,3JHH=6.8Hz,1H,CHCH3),3.77(d,2JHH=13.6Hz,1H,CH2C6H5),3.22-3.29(m,1H,CH2CH2),2.85-2.95(m,2H,CH2CH2),2.68-2.74(m,1H,CH2CH2),1.61(d,3JHH=6.8Hz,1H,CHCH3)。
Tetrahydroharmine的合成
250mL单口瓶中加入0.70g(2.29mmol)N-苄基保护的四氢Harmine,120mL三氟乙醇,0.70g Pd/C,通氢气搅拌过夜。脱溶,用二氯甲烷/甲醇(10∶1)进行常压柱层析得淡黄色粘稠物0.37g。收率80%,熔点195-197℃;1H NMR(400MHz,CDCl3)δ7.64(s,1H,NH),7.35(d,3JHH=8.8Hz,1H,Ar-H),6.85(d,4JHH=2.0Hz,1H,Ar-H),6.77(dd,3JHH=8.4Hz,4JHH=2.4Hz,1H,Ar-H),4.14-4.19(m,1H,CHCH3),3.84(s,3H,OCH3),3.33-3.39(m,1H,CH2CH2),3.01-3.07(m,1H,CH2CH2),2.66-2.78(m,2H,CH2CH2),1.65(s,1H,NH),1.44(d,3JHH=6.8Hz,3H,CH3);HRMS(ESI)calcd for C13H17N2O(M+H)+217.1335,found217.1337。
实施例4:Harmol的合成
100mL单口瓶中加入0.5g(2.36mmol)Harmine,18mL冰乙酸,18mL40%氢溴酸水溶液,加热回流10h。用饱和碳酸氢钠调节pH=8左右,有沉淀产生。抽滤得黄绿色固体0.46g。收率98%,熔点>300℃;1H NMR(400MHz,d6-DMSO)δ11.24(s,1H,NH),9.72(s,1H,OH),8.11(d,3JHH=5.2Hz,1H,Ar-H),7.94(d,3JHH=8.0Hz,1H,Ar-H),7.75(d,3JHH=5.2Hz,1H,Ar-H),6.90(d,4JHH=1.2Hz,1H,Ar-H),6.69(dd,3JHH=8.4Hz,4JHH=1.6Hz,1H,Ar-H),2.69(s,3H,CH3);HRMS(ESI)calcd for C12H11N2O(M+H)+199.0866,found199.0867。
实施例5:溴代和硝基取代Harmane的合成
溴代Harmane(Ia-1和Ia-2)的合成
25mL单口瓶中加入0.2g(1.10mmol)Harman,10mL冰乙酸,加入0.2g(1.10mmol)NBS,室温反应6h。脱溶,用饱和碳酸氢钠洗涤,二氯甲烷萃取,有机相用无水硫酸钠干燥,脱溶,依次用二氯甲烷/甲醇(40∶1→20∶1)进行常压柱层析得两个白色固体:固体Ia-10.05g,收率17%;1H NMR(400MHz,CDCl3)δ8.36-8.49(m,2H,NH and Ar-H),8.04(d,3JHH=6.4Hz,1H,Ar-H),7.77-7.84(m,1H,Ar-H),7.70(d,3JHH=6.4Hz,1H,Ar-H),7.18(t,3JHH=6.4Hz,1H,Ar-H),2.88(s,3H,CH3)。固体Ia-20.24g。收率83%.熔点256-257℃;1H NMR(400MHz,CDCl3)δ8.44(s,1H,NH),8.39(d,3JHH=5.6Hz,1H,Ar-H),8.24(d,4JHH=2.0Hz,1H,Ar-H),7.78(d,3JHH=5.6Hz,1H,Ar-H),7.63(dd,3JHH=8.4Hz,4JHH=2.0Hz,1H,Ar-H),7.42(d,3JHH=8.8Hz,1H,Ar-H),2.83(s,3H,CH3);HRMS(ESI)calcd for C12H10BrN2(M+H)+261.0022,found261.0026。
硝基取代的Harmane(Ia-3和Ia-4)的合成
50mL单口瓶中加入0.4g(2.20mmol)Harman,0.93g(10.99mmol)硝酸钠,加入20mL三氟乙酸,室温搅拌6h。向反应液中加入饱和碳酸氢钠水溶液调pH=10-11,有黄色沉淀产生,抽滤得黄色固体Ia-30.06g,收率12%,熔点207-210℃;1H NMR(400MHz,d6-DMSO)δ11.77(s,1H,NH),8.77(d,3JHH=7.6Hz,1H,Ar-H),8.50(d,3JHH=8.0Hz,1H,Ar-H),8.38(d,3JHH=5.2Hz,1H,Ar-H),8.11(d,3JHH=5.2Hz,1H,Ar-H),7.48(t,3JHH=7.6Hz,1H,Ar-H),2.92(s,3H,CH3);HRMS(ESI)calcd for C12H10N3O2(M+H)+228.0768,found228.0772。0.36g浅黄色固体Ia-4,收率72%,熔点>300℃;1H NMR(400MHz,d6-DMSO)δ12.36(s,1H,NH),9.30(d,4JHH=2.0Hz,1H,Ar-H),8.41(dd,3JHH=8.8Hz,4JHH=3.0Hz,1H,Ar-H),8.33(d,3JHH=5.6Hz,1H,Ar-H),8.20(d,3JHH=5.2Hz,1H,Ar-H),7.73(d,3JHH=8.4Hz,1H,Ar-H),2.79(s,3H,CH3);HRMS(ESI)calcd for C12H10N3O2(M+H)+228.0768,found228.0767。
实施例6:异丙胺基甲酸(1-甲基吡啶并[3,4-b]吲哚-7)-酯(Ia-5)的合成
100mL单口瓶中加入0.5g(2.53mmol)去甲基骆驼蓬碱,50mL DMF,加入1.5mL异氰酸异丙酯,和0.08g(0.758mmol)三乙胺,搅拌过夜。加入饱和氯化钠水溶液,用乙酸乙酯萃取,无水硫酸钠干燥,脱溶。用二氯甲烷/甲醇(20∶1)进行常压柱层析得0.50g白色固体。收率70%,熔点>300℃;1H NMR(400MHz,d6-DMSO)δ11.58(s,1H,NH),8.20(d,3JHH=5.2Hz,1H,Ar-H),8.16(d,3JHH=8.8Hz,1H,Ar-H),7.90(d,3JHH=5.2Hz,1H,Ar-H),7.76(d,3JHH=8.0Hz,1H,NHCO),7.27(d,4JHH=1.6Hz,1H,Ar-H),6.95(dd,3JHH=8.4Hz,4JHH=2.0Hz,1H,Ar-H),3.65-3.73(m,1H,CH),2.75(s,3H,CH3),1.16(d,3JHH=6.4Hz,6H,(CH3)2CH);HRMS(ESI)calcd for C16H18N3O2(M+H)+284.1394,found284.1399。
实施例7:二甲氨基甲酸(1-甲基吡啶并[3,4-b]吲哚-7)-酯(Ia-6)的合成
250mL单口瓶中加入0.4g(2.02mmol)去甲基骆驼蓬碱,150mL四氢呋喃,0.31g(3.03mmol)三乙胺,催化量的DMAP,室温搅拌0.5h,加入0.33g(3.03mmol)酰氯,搅拌过夜。脱溶,加入二氯甲烷和水分液,有机相用饱和食盐水洗,无水硫酸钠干燥,脱溶,用二氯甲烷/甲醇(10∶1)进行常压柱层析得白色固体0.48g。收率89%,熔点225-227℃;1H NMR(400MHz,d6-DMSO)δ11.63(s,1H,NH),8.20(d,3JHH=5.2Hz,1H,Ar-H),8.17(d,3JHH=8.4Hz,1H,Ar-H),7.91(d,3JHH=5.2Hz,1H,Ar-H),7.30(d,4JHH=2.0Hz,1H,Ar-H),6.97(dd,3JHH=8.4Hz,4JHH=2.0Hz,1H,Ar-H),3.10(s,3H,CH3),2.94(s,3H,CH3),2.75(s,3H,CH3);HRMS(ESI)calcd for C15H16N3O2(M+H)+270.1237,found270.1240。
化合物Ia-7-Ia-8通过重复上述步骤完成
乙酸(1-甲基吡啶并[3,4-b]吲哚-7)-酯(Ia-7)
白色固体,收率50%,熔点237-240℃;1H NMR(400MHz,CDCl3)δ8.90(s,1H,NH),8.23(d,3JHH=2.4Hz,1H,Ar-H),7.78(d,3JHH=8.4Hz,1H,Ar-H),7.70(d,3JHH=2.0Hz,1H,Ar-H),7.16(s,1H,Ar-H),6.93(d,3JHH=8.4Hz,1H,Ar-H),2.76(s,3H,CH3),2.42(s,3H,CH3CO).HRMS(ESI)calcd for C14H13N2O2(M+H)+241.0972,found241.0970。
特戊酸酸(1-甲基吡啶并[3,4-b]吲哚-7)-酯(Ia-8)
白色固体,收率85%,熔点221-222℃;1H NMR(400MHz,CDCl3)δ8.68(s,1H,NH),8.30(d,3JHH=5.2Hz,1H,Ar-H),7.75(d,3JHH=8.4Hz,1H,Ar-H),7.54(d,3JHH=4.8Hz,1H,Ar-H),7.09(s,1H,Ar-H),6.86(d,3JHH=8.0Hz,1H,Ar-H),2.73(s,3H,CH3),1.45(s,9H,C(CH3)3);HRMS(ESI)calcd for C17H19N2O2(M+H)+283.1441,found283.1446。
实施例8:(S)-3-甲基-2-苄氧羰基胺基丁酸-(1-甲基-吡啶并[3,4-b]吲哚-7)-酯(Ia-9)的合成
250mL单口瓶中加入0.80g(3.03mmol)氨基酸,150mL二氯甲烷,加入0.41g(4.04mmol)三乙胺,0.76g(4.04mmol)EDCI(1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐酸盐),0.50g(4.04mmol)DMAP(4-二甲氨基吡啶),搅拌过夜。水洗,无水硫酸钠干燥,脱溶,用二氯甲烷/甲醇(20∶1)进行常压柱层析得白色固体0.8g,收率92%,熔点69-71℃;1H NMR(400MHz,CDCl3)δ8.54(s,1H,NH),8.34(d,3JHH=5.2Hz,1H,Ar-H),7.92(d,3JHH=8.4Hz,1H,Ar-H),7.66(d,3JHH=4.8Hz,1H,Ar-H),7.35-7.38(m,5H,Ar-H),7.19(s,1H,Ar-H),6.94(d,3JHH=8.4Hz,1H,Ar-H),5.39(d,3JHH=8.4Hz,1H,NHCO),5.17(s,2H,CH2),4.54-4.66(m,1H,CHNH),2.77(s,3H,CH3),2.38-2.50(m,1H,CH(CH3)2),1.14(d,3JHH=6.8Hz,3H,CH(CH3)2),1.09(d,3JHH=6.8Hz,3H,CH(CH3)2);HRMS(ESI)calcd for C25H26N3O4(M+H)+432.1918,found432.1920。
实施例9:(1S,3S)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酸(Ib-1)
1000mL单口瓶中加入20g(98.0mmol)L-色氨酸,500mL水,2mL浓硫酸,20mL40%的乙醛水溶液,室温搅拌过夜,用浓氨水调pH=6-7,有白色固体析出,抽滤,得白色固体16.7g,收率74%,熔点78-280℃;1H NMR(400MHz,d6-DMSO)δ11.11(s,1H,COOH),7.45(d,3JHH=7.8Hz,1H,Ar-H),7.34(d,3JHH=8.0Hz,1H,Ar-H),7.09(t,3JHH=7.6Hz,1H,Ar-H),7.00(t,3JHH=7.2Hz,1H,Ar-H),4.52(q,3JHH=6.4Hz,1H,CH),3.61(dd,3JHH=11.6Hz,3JHH=4.4Hz,1H,CH),3.16(dd,2JHH=16.0Hz,3JHH=4.0Hz,1H,CH2),2.74-2.81(m,1H,CH2),1.62(d,3JHH=6.4Hz,3H,CH3);HRMS(ESI)calcd for C13H15N2O2(M+H)+231.1128,found231.1132。
化合物Ib-2和Ib-3通过重复上述步骤完成
(1R,3R)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酸(Ib-2)
白色固体,收率76%,熔点285-287℃;1H NMR(400MHz,d6-DMSO)δ11.20(s,1H,COOH),7.44(d,3JHH=7.6Hz,1H,Ar-H),7.35(d,3JHH=8.0Hz,1H,Ar-H),7.09(t,3JHH=7.6Hz,1H,Ar-H),7.00(t,3JHH=7.6Hz,1H,Ar-H),4.56(q,3JHH=6.4Hz,1H,CHCH3),3.64(dd,3JHH=12.0Hz,3JHH=4.8Hz,1H,CH),3.18(dd,2JHH=16.0Hz,3JHH=4.4Hz,1H,CH2),2.76-2.83(m,1H,CH2),1.64(d,3JHH=6.4Hz,3H,CH3);HRMS(ESI)calcd for C13H15N2O2(M+H)+231.1128,found231.1132。
(1S,3S)-1-乙基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酸(Ib-3)
白色固体2.67g,收率44%,熔点277-280℃;1H NMR(400MHz,d6-DMSO)δ10.92(s,1H,COOH),7.43(d,3JHH=7.6Hz,1H,Ar-H),7.32(d,3JHH=8.0Hz,1H,Ar-H),7.05-7.08(m,1H,Ar-H),6.96-7.00(m,1H,Ar-H),4.32-4.33(m,H,CHNH),3.54(dd,3JHH=11.6Hz,3JHH=4.4Hz,1H,CHCO),3.10(dd,3JHH=15.6Hz,3JHH=4.0Hz,1H,CH2),2.70-2.78(m,1H,CH2),2.12-2.20(m,1H,CH2CH3),1.83-1.90(m,1H,CH2CH3),1.01(t,3JHH=7.2Hz,3H,CH2CH3).HRMS(ESI)calcd for C14H17N2O2(M+H)+245.1285,found245.1289。
实施例10:2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酸(Ib-4)的合成
250mL单口瓶中加入10.00g(49mmol)L-色氨酸,1.96g(49mmol)氢氧化钠,100mL水,加入5mL30%甲醛水溶液。加热回流3h。用3M稀盐酸调pH=5左右,有沉淀产生,抽滤,滤饼水洗,干燥,得白色固体8.32g,收率88%,熔点278-279℃;1H NMR(400MHz,d6-DMSO)δ10.97(s,1H,COOH),7.45(d,3JHH=7.8Hz,1H,Ar-H),7.34(d,3JHH=8.0Hz,1H,Ar-H),7.09(t,3JHH=7.2Hz,1H,Ar-H),7.00(t,3JHH=7.2Hz,1H,Ar-H),4.25(d,2JHH=15.6Hz,1H,NHCH2),4.18(d,2JHH=15.6Hz,1H,NHCH2),3.62(dd,3JHH=10.4Hz,3JHH=4.8Hz,1H,CH),3.15(dd,2JHH=16.4Hz,3JHH=4.8Hz,1H,CH2),2.83(dd,3JHH=15.6Hz,3JHH=10.8Hz,1H,CH2);HRMS(ESI)calcd for C12H13N2O2(M+H)+217.0972,found217.0969。
实施例11:(1S,3S)-1-苯基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酸(Ib-5)的合成
100mL单口瓶中加入2.5g(12.3mmol)L-色氨酸,50mL冰乙酸,1.5g(13.5mmol)苯甲醛,加热回流12h,脱溶,用氨水调pH=5-6有沉淀产生,抽滤得白色固体3.1g,收率86%,熔点197-207℃;1H NMR(400MHz,d6-DMSO)δ10.46(s,1H,COOH),7.46(d,3JHH=7.6Hz,1H,Ar-H),7.39-7.41(m,5H,Ar-H),7.23(d,3JHH=8.0Hz,1H,Ar-H),7.03(t,3JHH=6.8Hz,1H,Ar-H),6.98(t,3JHH=7.6Hz,1H,Ar-H),5.43(s,1H,CH),4.95(br,1H,NH),3.80(dd,3JHH=11.2Hz,3JHH=4.0Hz,1H,CH),3.14(dd,2JHH=18.4Hz,3JHH=3.2Hz,1H CH2),2.86-2.92(m,1H,CH2);HRMS(ESI)calcd for C18H17N2O2(M+H)+293.1285,fOund293.1286。
化合物Ib-6通过重复上述步骤完成
(1S,3S)-1-(吡啶-3)-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酸(Ib-6)
黄色固体,收率87%,熔点250-253℃;1H NMR(400MHz,DMSO-d6)δ10.48(s,1H,COOH),8.60(d,4JHH=1.6Hz,1H,Ar-H),8.56(dd,3JHH=4.8Hz,4JHH=1.6Hz,1H,Ar-H),7.70(dt,3JHH=8.0Hz,4JHH=1.6Hz,1H,Ar-H),7.47(dd,3JHH=4.8Hz,3JHH=8.0Hz,1H,Ar-H),7.20(d,3JHH=7.6Hz,1H,Ar-H),7.00-7.04(m,1H,Ar-H),6.96-6.99(m,1H,Ar-H),5.37(s,1H,CHAr),3.79(dd,3JHH=11.2Hz,3JHH=4.0Hz,1H,CHCOOH),3.06-3.11(m,1H,CH2),2.81-2.88(m,1H,CH2);HRMS(ESI)calcd for C17H16N3O2(M+H)+294.1237,found294.1237。
实施例12:(1S,3S)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酸乙酯(Ib-13)的合成
1000mL单口瓶中加入16g(69.0mmol)酸,500mL无水乙醇,加入30mL二氯亚砜,加热回流5h。用饱和碳酸氢钠水溶液调pH=9有沉淀产生,抽滤得16.4g乳黄色固体,收率92%,熔点136-137℃;1H NMR(400MHz,CDCl3)δ7.86(s,1H,NH),7.49(d,3JHH=8.0Hz,1H,Ar-H),7.33(d,3JHH=8.0Hz,1H,Ar-H),7.17(t,3JHH=7.2Hz,1H,Ar-H),7.11(t,3JHH=7.2Hz,1H,Ar-H),4.26-4.31(m,3H,CH and OCH2),3.81(dd,3JHH=11.2Hz,3JHH=4.4Hz,1H,CH),3.13(dd,2JHH=15.2Hz,3JHH=4.0Hz,1H,CH2),2.79-2.86(m,1H,CH2),1.52(d,3JHH=6.4Hz,3H,CH3),1.35(t,3JHH=7.2Hz,3H,OCH2CH3);HRMS(ESI)calcd for C15H19N2O2(M+H)+259.1441,found259.1443。
化合物Ib-7-Ib-12通过重复上述步骤完成
(S)-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酸乙酯(Ib-7)
浅黄色固体,收率95%,熔点50-53℃;1H NMR(400MHz,CDCl3)δ7.81(s,1H,NH),7.48(d,3JHH=7.6Hz,1H,Ar-H),7.32(d,3JHH=8.0Hz,1H,Ar-H),7.17(t,3JHH=7.2Hz,1H,Ar-H),7.11(t,3JHH=7.2Hz,1H,Ar-H),4.25-4.30(m,3H,CH and OCH2),3.83-3.86(m,4H,CH and OCH3),3.11-3.16(m,1H,CH2),2.80-2.87(m,1H,CH2),1.51(d,3JHH=6.8Hz,3H,CH3);HRMS(ESI)calcd for C14H16N2O2(M+H)+245.1285,found245.1288。
(1S,3S)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酸丁酯(Ib-8)
黄色油状物,收率68%;1H NMR(400MHz,CDCl3)δ7.78(s,1H,NH),7.49(d,3JHH=7.6Hz,1H,Ar-H),7.33(d,3JHH=8.0Hz,1H,Ar-H),7.17(t,3JHH=7.2Hz,1H,Ar-H),7.11(t,3JHH=7.2Hz,1H,Ar-H),4.26-4.31(m,1H,CHCH3),4.23(t,3JHH=6.8Hz,2H,CH2O),3.82(dd,3JHH=7.2Hz,3JHH=4.4Hz1H,CHCO),3.10-3.16(m,1H,CH2),2.78-2.85(m,1H,CH2),1.67-1.74(m,2H,OCH2CH2),1.52(d,3JHH=6.8Hz,3H,CHCH3),1.41-1.48(m,2H,CH2CH3),0.97(t,3JHH=7.2Hz,3H,CH2CH3);HRMS(ESI)calcd for C17H23N2O2(M+H)+287.1754,found287.1759。
2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酸乙酯(Ib-9)
黄色固体,收率90%,熔点136-137℃;1H NMR(400MHz,CDCl3)δ7.80(s,1H,NH),7.49(d,3JHH=7.6Hz,1H,Ar-H),7.31(d,3JHH=8.0Hz,1H,Ar-H),7.16(td,3JHH=7.2Hz,4JHH=4.8Hz,1H,Ar-H),7.08-7.12(m,1H,Ar-H),4.26(q,3JHH=6.8Hz,2H,OCH2),4.10-4.19(m,2H,CH2NH),3.79(q,3JHH=4.8Hz,1H,CHCO),3.14(q,1H,3JHH=7.2Hz,1H,CHCO2Et),3.14(dd,2JHH=15.2Hz,3JHH=4.8Hz,1H,CH2),2.85-2.96(d,3JHH=6.4Hz,1H,CH2),1.93(br,1H,NH),1.33(t,3JHH=6.8Hz,3H,OCH2CH3);HRMS(ESI)calcd for C14H17N2O2(M+H)+245.1285,found245.1280。
(1S,3S)-1-乙基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酸乙酯(Ib-10)
黄色油状物,收率68%;1H NMR(400MHz,CDCl3)δ7.79(s,1H,NH),7.49(d,3JHH=7.6Hz,1H,Ar-H),7.33(d,3JHH=8.0Hz,1H,Ar-H),7.14-7.18(m,1H,Ar-H),7.09-7.13(m,1H,Ar-H),4.26-4.32(m,2H,OCH2),4.15-4.18(m,H,CHNH),3.78(dd,3JHH=11.2Hz,3JHH=4.0Hz,1H,CHCO),3.11-3.16(m,1H,CH2),2.77-2.84(m,1H,CH2),1.71-1.84(m,2H,CH3CH2),1.35(t,3JHH=7.2Hz,3H,OCH2CH3),1.90(t,3JHH=7.2Hz,3H,CH2CH3);HRMS(ESI)calcd forC16H21N2O2(M+H)+273.1598,found273.1602。
(1S,3S)-1-(吡啶-3)-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酸乙酯(Ib-11)
白色固体,收率42%,熔点239-240℃;1H NMR(400MHz,CDCl3)δ8.62(d,4JHH=1.6Hz,1H,Ar-H),8.55(dd,3JHH=4.4Hz,4JHH=1.6Hz,1H,Ar-H),7.94(s,1H,NH),7.72(dt,3JHH=7.6Hz,4JHH=1.6Hz,1H,Ar-H),7.55-7.58(m,1H,Ar-H),7.24-7.29(m,2H,Ar-H),7.11-7.19(m,2H,Ar-H),5.31(s,1H,CHAr),4.28-4.31(m,2H,OCH2CH3),3.97(dd,3JHH=11.2Hz,3JHH=4.0Hz,1H,CHCOOMe),3.26(ddd,3JHH=14.8Hz,3JHH=4.0Hz,4JHH=1.6Hz,1H,CH2),2.98-3.05(m,1H,CH2),1.35(t,3JHH=6.8Hz,3H,OCH2CH3);HRMS(ESI)calcd forC19H20N3O2(M+H)+322.1550,found322.1552。
(1R,3R)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酸乙酯(Ib-12)
浅黄色固体,收率92%,熔点121-122℃;1H NMR(400MHz,CDCl3)δ7.83(s,1H,NH),7.49(d,3JHH=7.6Hz,1H,Ar-H),7.32(d,3JHH=7.6Hz,1H,Ar-H),7.16(td,3JHH=7.2Hz,4JHH=1.2Hz,1H,Ar-H),7.11(td,3JHH=7.2Hz,4JHH=0.8Hz,1H,Ar-H),4.26-4.31(m,3H,CH andOCH2),3.81(dd,3JHH=11.2Hz,3JHH=4.4Hz,1H,CH),3.13(ddd,2JHH=15.2Hz,3JHH=4.4Hz,4JHH=2.0Hz,1H,CH2),2.82(ddd,2JHH=14.8Hz,3JHH=11.2Hz,4JHH=2.4Hz,1H,CH2),1.51(d,3JHH=6.8Hz,3H,CH3),1.35(t,3JHH=7.2Hz,3H,OCH2CH3);HRMS(ESI)calcd for C15H19N2O2(M+H)+259.1441,found259.1443。
实施例13:1-甲基-吡啶并[3,4-b]吲哚-3-甲酸乙酯(Ia-10)和1-甲基-吡啶并[3,4-b]吲哚-3-甲酸(Ia-11)
1-甲基-吡啶并[3,4-b]吲哚-3-甲酸乙酯(Ia-10)
250mL单口瓶中加入12.4g(47.7mmol)四氢咔啉,3.1g(95.4mmol)单质硫,150mL二甲苯,加热回流12h。冷却有肉红色固体析出,抽滤,得8.4g肉色固体。黄色固体,收率69%,熔点217-219℃;1H NMR(400MHz,CDCl3)δ9.60(s,1H,NH),8.79(s,1H,Ar-H),8.18(d,3JHH=8.0Hz,Ar-H),7.54-7.60(m,2H,Ar-H),7.32-7.36(m,1H,Ar-H),4.50(d,3JHH=6.8Hz,2H,OCH2),2.79(s,3H,CH3),1.41(t,3JHH=7.2Hz,3H,OCH2CH3);HRMS(ESI)calcd for C15H15N2O2(M+H)+227.0815,found227.0811。
1-甲基-吡啶并[3,4-b]吲哚-3-甲酸(Ia-11)
100mL单口瓶中加入酯2.00g(7.87mmol),0.47g(11.81mmol)氢氧化钠,60mL乙醇,加热回流6h。用3M稀盐酸调pH=5-6,有沉淀产生,抽滤,水洗滤饼,干燥,得淡黄色固体1.46g,收率82%,熔点>300℃;1H NMR(400MHz,d6-DMSO)δ12.04(s,1H,COOH),8.77(s,1H,Ar-H),8.36(d,3JHH=8.0Hz,1H,Ar-H),7.66(d,3JHH=8.0Hz,1H,Ar-H),7.60(t,3JHH=7.2Hz,1H,Ar-H),7.30(d,3JHH=7.2Hz,1H,Ar-H),7.31(d,3JHH=7.2Hz,1H,Ar-H),2.82(s,3H,CH3).HRMS(ESI)calcd for C13H11N2O2(M+H)+255.1128,found255.1131。
实施例14:(E)-3-(1-甲基-吡啶并[3,4-b]吲哚-3)-丙烯酸(Ia-14)的合成
(1-甲基-吡啶并[3,4-b]吲哚-3)-甲醇(Ia-12)
500mL单口瓶中加入酯2g(7.4mmol),300mL四氢呋喃,分批加入0.6g(15.7mmol)四氢铝锂,室温搅拌过夜,加水淬灭反应,抽滤,滤液脱溶得1.58g黄色固体,收率95%,熔点195-197℃;1H NMR(400MHz,d6-DMSO)δ11.46(s,1H,NH),8.19(d,3JHH=8.0Hz,1H,Ar-H),7.95(s,1H,Ar-H),7.56(d,3JHH=8.0Hz,1H,Ar-H),7.49-7.53(m,1H,Ar-H),7.18-7.22(m,1H,Ar-H),5.30(t,3JHH=6.0Hz,1H,OH),4.67(d,3JHH=6.0Hz,2H,CH2OH),2.73(s,3H,CH3)。
1-甲基-吡啶并[3,4-b]吲哚-3-甲醛(Ia-13)
100mL单口瓶中加入醇1.16g(5.47mnol),3.04g(10.93mmol)IBX,60mL DMSO,室温搅拌过夜。加入200mL水,用二氯甲烷萃取,饱和食盐水洗有机相,无水硫酸钠干燥,脱溶,用二氯甲烷/甲醇(10∶1)进行常压柱层析得白色固体0.46g,收率40%,熔点194-196℃;1HNMR(400MHz,d6-DMSO)δ12.17(s,1H,NH),10.07(s,1H,CHO),8.68(s,1H,Ar-H),8.38(d,3JHH=7.6Hz,1H,Ar-H),7.68(d,3JHH=8.0Hz,1H,Ar-H),7.61(t,3JHH=7.6Hz,1H,Ar-H),7.33(t,3JHH=7.6Hz,1H,Ar-H),2.87(s,3H,CH3)。
(E)-3-(1-甲基-吡啶并[3,4-b]吲哚-3)-丙烯酸(Ia-14)
250mL单口瓶中加入0.45g(2.14mmol)醛,100mL吡啶,3滴哌啶,加入0.33g(3.21mmol)丙二酸,加热反应4h。。水相用3M的稀盐酸调pH=5-6,抽滤,得黄色固体0.51g,收率94%,熔点220-223℃;1H NMR(400MHz,d6-DMSO)δ12.22(s,1H,NH),11.85(s,1H,COOH),8.31(s,1H,Ar-H),8.21(d,3JHH=7.6Hz,1H,Ar-H),7.72(d,3JHH=15.2Hz,1H,CHCH),7.62(d,3JHH=7.6Hz,1H,Ar-H),7.56(t,3JHH=7.6Hz,1H,Ar-H),7.28(t,3JHH=7.6Hz,1H,Ar-H),6.78(d,3JHH=15.6Hz,1H,CHCH),2.80(s,3H,CH3);HRMS(ESI)calcd for C15H13N2O2(M+H)+253.0972,found253.0975。
化合物Ia-15-Ia-16通过重复上述步骤完成
(E)-3-(1-(噻吩-2)-吡啶并[3,4-b]吲哚-3)-丙烯酸(Ia-15)
黄色固体,收率85%,熔点248-250℃;1H NMR(400MHz,d6-DMSO)δ12.43(s,1H,NH),12.10(s,1H,COOH),8.47(s,1H,Ar-H),8.28(d,3JHH=8.0Hz,1H,Ar-H),8.17(d,3JHH=3.2Hz,1H,Ar-H),7.80(d,3JHH=4.8Hz,1H,Ar-H),7.77-7.80(m,2H,Ar-H),7.62(t,3JHH=7.2Hz,1H,Ar-H),7.33-7.38(m,2H,Ar-H and CHCH),6.88(d,3JHH=15.6Hz,1H,CHCH),6.93(d,3JHH=15.6Hz,1H,CHCH);HRMS(ESI)calcd for C18H13N2O2S(M+H)+321.0692,found321.0694。
(E)-3-(1-(吡啶-3)-吡啶并[3,4-b]吲哚-3)-丙烯酸(Ia-16)
黄色固体,收率50%,熔点>300℃;1H NMR(400MHz,d6-DMSO)δ12.43(s,1H,NH),12.10(s,1H,COOH),9.31(d,4JHH=1.6Hz,1H,Ar-H),8.81(dd,3JHH=4.8Hz,4JHH=1.2Hz,1H,Ar-H),8.61(s,1H,Ar-H),8.56-8.59(m,1H,Ar-H),8.31(d,3JHH=7.6Hz,1H,Ar-H),7.84(d,3JHH=15.6Hz,1H,CHCH),7.76(dd,3JHH=7.6Hz,4JHH=4.8Hz,1H,Ar-H),7.70(d,3JHH=8.0Hz,1H,Ar-H),7.62(t,3JHH=7.2Hz,1H,Ar-H),7.35(t,3JHH=7.2Hz,1H,Ar-H),6.93(d,3JHH=15.6Hz,1H,CHCH);
实施例15:1-甲基-4,9-二氢-吡啶并[3,4-b]吲哚-3-甲酸乙酯(Ib-14)的合成
L-色氨酸乙酯(6)
250mL单口瓶中加入L-色氨酸0.50g(24.50mmol),150mL乙醇,加入15mL二氯亚砜,加热回流12h。脱溶,脱溶,得5.72g棕色粘稠物,收率98%;1HNMR(400MHz,CDCl3)δ8.10(s,1H,NH),7.62(d,3JHH=7.6Hz,1H,Ar-H),7.37(d,3JHH=8.0Hz,1H,Ar-H),7.20(t,3JHH=7.2Hz,1H,Ar-H),7.13(t,3JHH=7.2Hz,1H,Ar-H),7.08(s,1H,Ar-H),4.14-4.19(m,2H,OCH2),3.82(dd,3JHH=7.6Hz,3JHH=5.2Hz,1H,CH),3.29(dd,2JHH=14.4Hz,3JHH=5.2Hz,1H,CH2),3.05(dd,2JHH=14.4Hz,3JHH=8.0Hz,1H,CH2),1.24(t,3JHH=7.2Hz,3H,OCH2CH3)。
1-甲基-4,9-二氢-吡啶并[3,4-b]吲哚-3-甲酸乙酯(Ib-14)
250mL单口瓶中加入色氨酸乙酯5.72g(24.66mmol),150mL二氯甲烷,2.99g(29.59mmol)三乙胺,加入2.13g(27.12mmol)乙酰氯,滴毕,室温搅拌5h。用饱和碳酸氢钠洗反应液,二氯甲烷萃取,饱和食盐水洗有机相,无水硫酸钠干燥,脱溶,得5.96g棕色粘稠物。用氯仿溶解,加入24mL POCl3,加热回流5h。二氯甲烷萃取,无水硫酸钠干燥,脱溶,用二氯甲烷/甲醇(10∶1)进行常压柱层析得2.85g黄色固体。黄色固体,收率45%,熔点85-87℃;1HNMR(400MHz,CDCl3)δ8.33(s,1H,NH),7.61(d,3JHH=8.0Hz,1H,Ar-H),7.41(d,3JHH=8.0Hz,1H,Ar-H),7.30(t,3JHH=8.0Hz,1H,Ar-H),7.17(t,3JHH=8.0Hz,1H,Ar-H),4.43-4.48(m,1H,CHCO2Et),4.31(q,3JHH=7.2Hz,OCH2),3.25(dd,2JHH=16.4Hz,3JHH=7.6Hz,1H,CH2CH),3.08(dd,2JHH=16.4Hz,3JHH=14.8Hz,1H,CH2CH),2.43(d,3JHH=2.0Hz,3H,CH3),1.34(t,3JHH=7.2Hz,3H,OCH2CH3);HRMS(ESI)calcd for C15H17N2O2(M+H)+257.1285,found257.1287。
实施例16:(1S,3S)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ib-15)
100mL单口瓶中加入甲酯1.00g(4.1mmol),50mL乙醇,1.02g(16.4mmol)80%水合肼,加热回流6h。脱溶,用乙酸乙酯溶解,饱和食盐水洗,无水硫酸钠干燥,脱溶,得淡黄色固体0.98g。收率98%。白色固体,收率98%,熔点100-103℃;1H NMR(400MHz,CDCl3)δ8.15(s,1H,NH),7.90(s,1H,NHCO),7.50(d,3JHH=7.6Hz,1H,Ar-H),7.32(d,3JHH=8.0Hz,1H,Ar-H),7.17(t,3JHH=7.2Hz,1H,Ar-H),7.11(t,3JHH=7.2Hz,1H,Ar-H),4.18-4.23(m,1H,CHCH3),3.93(br,2H,NH2),3.65(q,3JHH=8.4Hz,1H,CHCO),3.26-3.32(m,1H,CH2),2.71-2.78(m,1H,CH2),1.48(d,3JHH=6.8Hz,3H,CH3);HRMS(ESI)calcd for C13H17N4O(M+H)+245.1397,found245.1398。
实施例17:(1S,3S)-N-丁基-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-16)的合成
25mL单口瓶中加入甲酯0.5g(2.05mmol),15mL正丁胺,室温搅拌过夜。脱溶,加入二氯甲烷溶解,用饱和食盐水洗涤,无水硫酸钠干燥,脱溶。用二氯甲烷/甲醇(20∶1)进行常压柱层析得白色固体0.35g,收率60%,熔点207-210℃;1H NMR(400MHz,CDCl3)δ8.02(s,1H,NH),7.49(d,3JHH=8.0Hz,1H,Ar-H),7.31(d,3JHH=7.6Hz,1H,Ar-H),7.15(t,3JHH=7.2Hz,1H,Ar-H),7.10(t,3JHH=7.2Hz,1H,Ar-H),4.17-4.22(m,1H,CHCH3),3.58(dd,3JHH=11.2Hz,3JHH=4.4Hz1H,CHCO),3.28-3.38(m,3H,CHCH2and NHCH2),2.37-2.74(m,1H,CH2),1.51-1.59(m,2H,NHCH2CH2),1.49(d,3JHH=10.8Hz,3H,CHCH3),1.34-1.43(m,2H,CH2CH3),095(t,3JHH=7.2Hz,3H,CH2CH3);HRMS(ESI)calcd for C17H24N3O(M+H)+286.1914,found286.1919。
化合物Ib-18通过重复上述步骤完成
(1S,3S)-N-(2羟乙基)-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-18)
白色固体,收率64%,熔点110-112℃;1H NMR(400MHz,d4-methanol)δ7.39(d,3JHH=7.6Hz,1H,Ar-H),7.29(d,3JHH=8.0Hz,1H,Ar-H),7.04-7.07(m,1H,Ar-H),6.95-6.99(m,1H,Ar-H),4.18(q,3JHH=6.8Hz,1H,CHCH3),3.67(t,3JHH=6.4Hz,2H,HOCH2),3.62(dd,3JHH=11.2Hz,3JHH=4.4Hz1H,CHCO),3.38-3.42(m,3H,NHCH2),.3.30-3.32(m,1H,?),3.02-3.08(m,1H,CH2CHCO),2.72-2.80(m,1H,CH2CHCO),1.52(d,3JHH=6.8Hz,3H,CHCH3);HRMS(ESI)calcd for C15H20N3O2(M+H)+274.1550,found274.1552。
实施例18:(1S,3S)-N-环己基-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-17)的合成
白色固体,收率50%,熔点231-233℃;1H NMR(400MHz,CDCl3)δ7.81(s,1H,NH),7.51(d,3JHH=8.0Hz,1H,Ar-H),7.32(d,3JHH=8.0Hz,1H,Ar-H),7.14-7.18(m,1H,Ar-H),7.09-7.13(m,1H,Ar-H),6.94(d,3JHH=8.0Hz,1H,NHCO),4.19-4.24(m,1H,CHCH3),3.79-3.88(m,1H,NHCH),3.57(dd,3JHH=11.2Hz,4JHH=4.8Hz1H,CHCO),3.28-3.33(m,1H,COCHCH2),2.67-2.74(m,1H,COCHCH2),1.93-1.99(m,2H,CH2),1.73-1.73(m,2H,CH2),1.58-1.67(m,2H,CH2),1.50(d,3JHH=8.0Hz,3H,CHCH3),1.36-1.43(m,2H,CH2),1.18-1.26(m,2H,CH2);HRMS(ESI)calcd for C19H26N3O(M+H)+312.2070,found312.2076。
化合物Ib-19,Ib-20通过重复上述步骤完成
(1S,3S)-N-((二甲氨基)甲基)-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-19)
白色固体,收率55%,mp=110-112℃;1H NMR(400MHz,CDCl3)δ7.87(s,1H,Ar-NH),7.51(d,3JHH=8.0Hz,1H,Ar-H),7.32(d,3JHH=7.6Hz,1H,Ar-H),7.28(m.1H,CONH),7.16(t,3JHH=7.2Hz,1H,Ar-H),7.11(t,3JHH=7.2Hz,1H,Ar-H),4.22(q,3JHH=6.8Hz,1H,CH),3.61(dd,3JHH=4.4Hz,3JHH=11.2Hz,1H,CH),3.51-3.36(m,2H,N-CH2),3.28(ddd,4JHH=2.0Hz,3JHH=4.4Hz,2JHH=16.0Hz,1H,CH2),2.74(ddd,4JHH=2.4Hz,3JHH=11.2Hz,2JHH=16.0Hz,1H,CH2),2.48(t,3JHH=6.4Hz,2H,CH2),2.27(s,6H,CH3),1.50(d,3JHH=6.8Hz,3H,CH3);HRMS(ESI)calcd for C17H25N4O(M+H)+301.2023,found301.2027。
(1S,3S)-N-((四氢呋喃-2)-甲基)-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-20)
黄色固体,收率47%,熔点95-97℃;1H NMR(400MHz,CDCl3)δ7.81(s,1H,NH),7.55(d,3JHH=7.6Hz,1H,Ar-H),7.40-7.45(m,1H,NHCO),7.36(d,3JHH=7.6Hz,1H,Ar-H),7.20(t,3JHH=7.6Hz,1H,Ar-H),7.14(t,3JHH=7.6Hz,1H,Ar-H),4.25(q,3JHH=6.8Hz,1H,CHCH3),4.04-4.10(m,1H,CHO),3.90-3.95(m,1H,CH2O),3.83(dd,3JHH=7.2Hz,3JHH=15.2Hz,1H,CHCO),3.63-3.70(m,2H,CH2O and CH2NH),3.35(dd,2JHH=16.0Hz,3JHH=4.4Hz,1H,CH2CH),3.18-3.30(m,1H,CH2NH),2.72-2.79(m,1H,CH2CH),2.02-2.08(m,1H,CH2CH2),1.92-1.99(m,2H,CH2CH2),1.59-1.65(m,1H,CH2CH2),1.53(d,3JHH=6.8Hz,3H,CHCH3);HRMS(ESI)calcd for C18H23N3O2(M+H)+314.1863,found314.1867。
实施例19:(1S,3S)-N′-苯亚甲基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-1)
100mL单口瓶中加入0.50g(2.05mmol)酰肼,40mL甲苯,加入0.44g(4.10mmol)苯甲醛,加热回流5h。抽滤,以甲苯洗涤,得黄色固体0.50g,收率74%,熔点200-204℃;1H NMR(400MHz,DMSO-d6)δ11.48and11.35(s,1H,NH),10.84and10.81(s,1H,O=C-NH),8.34and8.06(s,1H,N=CH),7.71and7.61(dd,4JHH=1.6Hz,3JHH=7.6Hz,1H,Ph-H),7.49-7.42(m,2H,Ph-H),7.42-7.33(m,2H,Ph-H and Ar-H),7.31and7.30(d,3JHH=8.0Hz,1H,Ar-H),7.03(t,3JHH=7.2Hz,1H,Ar-H),6.95and6.92(t,3JHH=7.2Hz,1H,Ar-H),4.48and3.61(dd,3JHH=10.8Hz,3.6Hz,1H,CH),4.15(q,3JHH=8.0Hz,1H,CH),2.98-2.89(m,1H,CH2),2.71and2.62(ddd,4JHH=2.0Hz,3JHH=11.6Hz,2JHH=14.4Hz,1H,CH2),1.45(d,3JHH=6.8Hz,3H,CH3);HRMS(ESI)calcd for C20H21N4O[M+H]+333.1710,found333.1715。
化合物Ic-2-Ic-29通过重复上述步骤完成
(1S,3S)-N’-(4-叔丁基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-2)
黄色固体,收率72%,熔点139-143℃;1H NMR(400MHz,DMSO-d6)δ11.47and11.32(s,1H,NH),10.87and10.82(s,1H,O=C-NH),8.31and8.03(s,1H,N=CH),7.88and7.70-7.27(m,6H,Ph-H and Ar-H),7.04(t,3JHH=6.8Hz,1H,Ar-H),6.96(t,3JHH=7.2Hz,1H,Ar-H),4.48and3.62(dd,3JHH=10.4Hz,7.2Hz,1H,CH),4.27-4.08(m,1H,CH),3.02-2.88(m,1H,CH2),2.77-2.59(m,1H,CH2),1.52-1.35(m,3H,CH3),1.30and1.24(s,9H,CH3);HRMS(ESI)calcdfor C24H29N4O[M+H]+389.2336,found389.2338。
(1S’3S)-N’-(4-二甲氨基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-3)
黄色固体,收率73%,熔点215-220℃;1H NMR(400MHz,DMSO-d6)δ11.20and11.05(s,1H,NH),10.84and10.80(s,1H,O=C-NH),8.16and7.92(s,1H,N=CH),7.52and7.36(d,3JHH=7.6Hz,2H,Ph-H),7.44-7.38(m,1H,Ar-H),7.30(d,3JHH=6.4Hz,1H,Ar-H),7.03(t,3JHH=6.8Hz,1H,Ar-H),6.95(t,3JHH=6.8Hz,1H,Ar-H),6.75and6.67(d,3JHH=7.6Hz,2H,Ph-H),4.44and3.57(d,3JHH=8.8Hz,1H,CH),4.23-4.08(m,1H,CH),3.07-2.86(m,7H,N-CH3and CH2),2.74-2.56(m,1H,CH2),1.52-1.38(m,3H,CH3);HRMS(ESI)calcd for C22H26N5O[M+H]+376.2132,found376.2137。
(1S’3S)-N’-(4-硝基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-4)
黄色固体,收率74%,熔点222-227℃;1H NMR(400MHz,DMSO-d6)δ11.81and11.68(s,1H,NH),10.87and10.82(s,1H,O=C-NH),8.46and8.17(s,1H,N=CH),8.31and8.22(d,3JHH=8.4Hz,2H,Ph-H),7.98and7.88(d,3JHH=8.4Hz,2H,Ph-H),7.41and7.36(d,3JHH=7.6Hz,1H,Ar-H),7.31(d,3JHH=6.4Hz,1H,Ar-H),7.04(t,3JHH=7.2Hz,1H,Ar-H),6.96(t,3JHH=7.6Hz,1H,Ar-H),4.55and3.67(d,3JHH=8.8Hz,1H,CH),4.25--4.10(m,1H,CH),2.96(d,2JHH=13.6Hz,1H,CH2),2.79-2.60(m,1H,CH2),1.47(d,3JHH=6.4Hz,3H,CH3);HRMS(ESI)calcd for C20H20N5O[M+H]+378.1561,found378.1563。
(1S’3S)-N’-(4-氯苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-5)
黄色固体,收率81%,熔点140-145℃;1H NMR(400MHz,DMSO-d6)δ11.62and11.51(s,1H,NH),10.91and10.85(s,1H,O=C-NH),8.35and8.07(s,1H,N=CH),7.74and7.64(d,3JHH=7.2Hz,2H,Ph-H),7.58-7.35(m,3H,Ph-H and Ar-H),7.35-7.28(m,1H,Ar-H),7.10-7.00(m,1H,Ar-H),7.00-6.90(m,1H,Ar-H),4.56and3.66(d,3JHH=9.6Hz,1H,CH),4.30-4.12(m,1H,CH),3.03-2.90(m,1H,CH2),2.79-2.62(m,1H,CH2),1.54-1.39(m,3H,CH3);HRMS(ESI)calcd forC20H20N4OCl[M+H]+367.1320,found367.1323。
(1S,3S)-N’-(2,4-二氯苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-6)
黄色固体,收率85%,熔点211-213℃;1H NMR(400MHz,DMSO-d6)δ11.82and11.77(s,1H,NH),10.91and10.84(s,1H,O=C-NH),8.71and8.42(s,1H,N=CH),8.00and7.85(d,3JHH=8.4Hz,1H,Ph-H),7.73and7.71(d,4JHH=2.0Hz,1H,Ph-H),7.53and7.43-7.35(dd,4JHH=2.0Hz,3JHH=8.4Hz,1H,Ph-H),7.41and7.37(d,3JHH=8.0Hz,1H,Ar-H),7.32and7.31(d,3JHH=8.0Hz,1H,Ar-H),7.04(t,3JHH=7.2Hz,1H,Ar-H),6.96and6.94(t,3JHH=7.2Hz,1H,Ar-H),4.65-4.56and3.66(dd,3JHH=10.4Hz,3.6Hz,1H,CH),4.35-4.13(m,1H,CH),3.06-2.91(m,1H,CH2),2.78-2.64(m,1H,CH2),1.54-1.43(m,3H,CH3);HRMS(ESI)calcd forC20H19N4OCl2[M+H]+401.0931,found401.0929。
(1S,3S)-N’-(3,4-二氯苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-7)
黄色固体,收率79%,熔点189-193℃;1HNMR(400MHz,DMSO-d6)δ11.84and11.67(s,1H,NH),10.98and10.86(s,1H,O=C-NH),8.34and8.07(s,1H,N=CH),7.94and7.88(s,1H,Ph-H),7.72and7.64(s,2H,Ph-H),7.41and7.39(d,3JHH=8.4Hz,1H,Ar-H),7.33and7.31(d,3JHH=8.4Hz,1H,Ar-H),7.06and7.04(t,3JHH=7.2Hz,1H,Ar-H),6.96and6.96(t,3JHH=7.2Hz,1H,Ar-H),4.68and3.70(dd,3JHH=10.4Hz,4.4Hz,1H,CH),4.38and4.19(q,3JHH=6.4Hz,1H,CH),3.06and2.98(dd,3JHH=3.6Hz,2JHH=14.4Hz,1H,CH2),2.80-2.66(m,1H,CH2),1.53and1.48(d,3JHH=6.4Hz,3H,CH3);HRMS(ESI)calcd for C20H19N4OCl2[M+H]+401.0931,found401.0934。
(1S,3S)-N’-(4-甲氧基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-8)
黄色固体,收率69%,熔点138-143℃;1H NMR(400MHz,DMSO-d6)δ11.35and11.22(s,1H,NH),10.84and10.81(s,1H,O=C-NH),8.27and8.00(s,1H,N=CH),7.65and7.55(d,3JHH=8.0Hz,2H,Ph-H),7.40and7.36(d,3JHH=7.6Hz,1H,Ar-H),7.30(d,3JHH=7.6Hz,1H,Ar-H),7.08-6.89(m,4H,Ar-H and Ph-H),4.45and3.59(d,3JHH=8.8Hz,1H,CH),4.20-4.08(m,1H,CH),3.81and3.74(s,3H,O-CH3),2.93(d,2JHH=14.4Hz,1H,CH2),2.76-2.56(m,1H,CH2),1.45(d,3JHH=6.0Hz,3H,CH3);HRMS(ESI)calcd for C21H23N4O2[M+H]+363.1816,found363.1819。
(1S,3S)-N’-(3甲氧基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-9)
黄色固体,收率63%,熔点186-190℃;1H NMR(400MHz,DMSO-d6)δ11.54and11.39(s,1H,NH),10.87and10.83(s,1H,O=C-NH),8.32and8.03(s,1H,N=CH),7.45-7.11(m,5H,Ph-H and Ar-H),7.08-6.89(m,3H,Ar-H and Ph-H),4.48and3.63(d,3JHH=8.0Hz,1H,CH),4.25-4.10(m,1H,CH),3.81and3.69(s,3H,O-CH3),3.02-2.89(m,1H,CH2),2.77-2.60(m,1H,CH2),1.46(d,3JHH=5.2Hz,3H,CH3);HRMS(ESI)calcd for C21H23N4O2[M+H]+363.1816,found363.1818。
(1S,3S)-N’-(2-甲氧基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-10)
黄色固体,收率82%,熔点180-183℃;1HNMR(400MHz,DMSO-d6)δ11.52and11.46(s,1H,NH),10.90and10.84(s,1H,O=C-NH),8.66and8.41(s,1H,N=CH),7.84and7.68(d,3JHH=7.2Hz,1H,Ph-H),7.41(d,3JHH=7.6Hz,1H,Ar-H),7.37(d,3JHH=7.6Hz,1H,Ar-H),7.31(dd,3JHH=8.0Hz,4.0Hz,1H,Ph-H),7.14-6.86(m,4H,Ph-H and Ar-H),4.54and3.61(dd,3JHH=10.0Hz,2.8Hz,1H,CH),4.30-4.10(m,1H,CH),3.86and3.84(s,3H,O-CH3),3.04-2.89(m,1H,CH2),2.77-2.60(m,1H,CH2),1.55-1.37(m,3H,CH3);HRMS(ESI)calcd for C21H23N4O2[M+H]+363.1816,found363.1823。
(1S,3S)-N’-(3,4-二甲氧基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-11)
浅黄色固体,收率91%,熔点203-206℃;1H NMR(400MHz,DMSO-d6)δ11.47and11.27(s,1H,NH),10.89and10.83(s,1H,O=C-NH),8.25and7.99(s,1H,N=CH),7.43-7.36(m,1H,Ar-H),7.34-7.27and7.22-7.15(m,3H,Ar-H and Ph-H),7.07-6.91(m,3H,Ar-H and Ph-H),4.49and3.67-3.59(dd,3JHH=11.2Hz,3.6Hz,1H,CH),4.33-4.11(m,1H,CH),3.82and3.75(s,3H,O-CH3),3.81and3.64(s,3H,O-CH3),3.03and2.94(dd,3JHH=2.8Hz,2JHH=14.8Hz,1H,CH2),2.76-2.65(m,1H,CH2),1.48and1.46(d,3JHH=6.8Hz,3H,CH3);HRMS(ESI)calcd for C22H25N4O3[M+H]+393.1921,found393.1918。
(1S,3S)-N’-((苯并[d][1,3]二氧亚甲基-5)-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-12)
黄色固体,收率83%,收率199-203℃;1H NMR(400MHz,DMSO-d6)δ11.41and11.26(s,1H,NH),10.86and10.81(s,1H,O=C-NH),8.24and7.96(s,1H,N=CH),7.40and7.36(d,3JHH=7.6Hz,1H,Ar-H),7.31and7.30(d,3JHH=8.0Hz,1H,Ar-H),7.28and7.17(s,1H,Ph-H),7.15and7.09(d,3JHH=8.0Hz,1H,Ph-H),7.06-6.96(m,2H,Ar-H and Ph-H),6.94(t,3JHH=7.6Hz,1H,Ar-H),6.10(s,1H,O-CH2),6.02(d,2JHH=4.8Hz,1H,O-CH2),4.49and3.60(dd,3JHH=10.8Hz,3.6Hz,1H,CH),4.22and4.13(m,1H,CH),2.99-2.87(m,1H,CH2),2.75-2.57(m,1H,CH2),1.45(d,3JHH=6.4Hz,3H,CH3);HRMS(ESI)calcd for C21H21N4O3[M+H]+377.1608,found377.1615。
(1S,3S)-N’-((2,3-二氢苯并[b][1,4]二氧芑-6-亚甲基)-1-甲基)-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-13)
浅黄色固体,收率81%,熔点204-207℃;1H NMR(400MHz,DMSO-d6)δ11.44and11.26(s,1H,NH),10.89and10.82(s,1H,O=C-NH),8.21and7.94(s,1H,N=CH),7.40and7.36(d,3JHH=7.6Hz,1H,Ar-H),7.32and7.30(d,3JHH=8.0Hz,1H,Ar-H),7.20and7.10(s,1H,Ph-H),7.19and7.09(d,3JHH=7.6Hz,1H,Ph-H),7.07-7.01(m,1H,Ar-H),6.99-6.83(m,2H,Ar-Hand Ph-H),4.51and3.61(dd,3JHH=10.8Hz,3.6Hz,1H,CH),4.35-4.09(m,5H,CH and O-CH2-CH2-O),3.03-2.89(m,1H,CH2),2.76-2.60(m,1H,CH2),1.53-1.43(m,3H,CH3);HRMS(ESI)calcd for C22H23N4O3[M+H]+391.1765,found391.1763。
(1S,3S)-N’-(6-羟基萘-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4b]吲哚-3-甲酰肼(Ic-14)
黄色固体,收率70%,熔点275-278℃;1H NMR(400MHz,DMSO-d6)δ11.46and11.35(s,1H,NH),10.85and10.81(s,1H,O=C-NH),9.98(s,1H,OH),8.42and8.16(s,1H,N=CH),7.99and7.91(s,1H,Naphthalene-H),7.85(d,3JHH=9.2Hz,1H,Naphthalene-H),7.80and7.61(d,3JHH=8.8Hz,1H,Naphthalene-H),7.74and7.70(d,3JHH=8.8Hz,1H,Naphthalene-H),7.42and7.37(d,3JHH=7.6Hz,1H,Ar-H),7.16and7.08(s,1H,Naphthalene-H),7.15-7.09(m,1H,Naphthalene-H),7.04(t,3JHH=7.6Hz,1H,Ar-H),7.00-6.90(m,1H,Ar-H),4.52and3.63(d,3JHH=8.4Hz,1H,CH),4.25-4.10(m,1H,CH),3.02-2.90(m,1H,CH2),2.73and2.65(t,2JHH=12.8Hz,1H,CH2),1.47(d,3JHH=6.0Hz,3H,CH3);HRMS(ESI)calcd for C24H23N4O2[M+H]+399.1816,found399.1822。
(1S,3S)-N’-(吡啶-4-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-15)
黄色固体,收率79%,熔点235-239℃;1H NMR(400MHz,DMSO-d6)δ11.84and11.69(s,1H,NH),10.90and10.84(s,1H,O=C-NH),8.65and8.57(d,3JHH=5.6Hz,2H,Py-H),8.35and8.05(s,1H,N=CH),7.65and7.57(d,3JHH=5.6Hz,2H,Py-H),7.41and7.37(d,3JHH=7.6Hz,1H,Ph-H),7.34-7.29(m,1H,Ar-H),7.04(t,3JHH=7.6Hz,1H,Ar-H),6.95(t,3JHH=7.6Hz,1H,Ar-H),4.58and3.67(dd,3JHH=10.8Hz,3.6Hz,1H,CH),4.26and4.16(q,3JHH=6.4Hz,1H,CH),3.05-2.91(m,1H,CH2),2.80-2.62(m,1H,CH2),1.48(d,3JHH=6.4Hz,3H,CH3);HRMS(ESI)calcd For C19H20N5O[M+H]+334.1662,found334.1663。
(1S,3S)-N’-(吡啶-3-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-16)
黄色固体,收率72%,熔点205-209℃;1HNMR(400MHz,DMSO-d6)δ11.74and11.58(s,1H,NH),10.91and10.84(s,1H,O=C-NH),8.84and8.79(s,1H,Py-H),8.62and8.55(d,3JHH=4.0Hz,1H,Py-H),8.41and8.12(s,1H,N=CH),8.12and8.03(d,3JHH=4.0Hz,1H,Py-H),7.49and7.44-7.35(m,2H,Py-H and Ar-H),7.33and7.31(d,3JHH=7.6Hz,1H,Ph-H),7.04(t,3JHH=7.6Hz,1H,Ar-H),6.96(t,3JHH=7.6Hz,1H,Ar-H),4.59and3.66(dd,3JHH=10.8Hz,3.6Hz,1H,CH),4.32and4.12(m,1H,CH),3.05-2.92(m,1H,CH2),2.78-2.63(m,1H,CH2),1.53-1.39(m,3H,CH3);HRMS(ESI)calcd for C19H20N5O[M+H]+334.1662,found334.1664。
(1S,3S)-N’-(吡啶-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-17)
黄色固体,收率85%,熔点245-249℃;1H NMR(400MHz,DMSO-d6)δ11.69and11.65(s,1H,NH),10.85and10.82(s,1H,O=C-NH),8.62and8.57(d,3JHH=4.8Hz,1H,Py-H),8.36and8.10(s,1H,N=CH),7.95and7.80(d,3JHH=8.0Hz,1H,Py-H),7.88and7.75(td,4JHH=1.2Hz,3JHH=7.6Hz,1H,Py-H),7.44-7.33(m,2H,Py-H and Ar-H),7.31and7.30(d,3JHH=7.6Hz,1H,Ar-H),7.03(t,3JHH=7.2Hz,1H,Ar-H),6.95and6.92(t,3JHH=7.2Hz,1H,Ar-H),4.50and3.63(dd,3JHH=10.8Hz,4.0Hz,1H,CH),4.16(q,3JHH=8.0Hz,1H,CH),2.94(ddd,4JHH=1.6Hz,3JHH=4.4Hz,2JHH=14.8Hz,1H,CH2),2.72and2.63(ddd,4JHH=2.0Hz,3JHH=10.8Hz,2JHH=14.8Hz,1H,CH2),1.46and1.45(d,3JHH=6.8Hz,3H,CH3);HRMS(ESI)calcd forC19H20N5O[M+H]+334.1662,found334.1666。
(1S,3S)-N’-(呋喃-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-18)
黄色固体,收率62%,熔点144-148℃;1H NMR(400MHz,CDCl3)δ10.33and10.20(s,1H,NH),8.26and8.11(s,1H,O=C-NH),8.04and7.72(s,1H,N=CH),7.51-7.38(m,2H,Ar-Hand furan-H),7.34and7.31(d,3JHH=7.6Hz,1H,Ar-H),7.14(t,3JHH=6.8Hz,1H,Ar-H),7.08(t,3JHH=7.2Hz,1H,Ar-H),6.77and6.62(s,1H,furan-H),6.45and6.42(s,1H,furan-H),4.65and3.69(d,3JHH=7.6Hz,1H,CH),4.32-4.11(m,1H,CH),3.30and3.19(d,2JHH=13.6Hz,1H,CH2),2.79(t,2JHH=13.2Hz,1H,CH2),1.97(br,1H,NH),1.52and1.46(d,3JHH=6.4Hz,3H,CH3);HRMS(ESI)calcd for C18H19N4O2[M+H]+323.1503,found323.1505。
(1S,3S)-N’-(吡咯-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-19)
红色固体,收率75%,熔点207-209℃;1H NMR(400MHz,DMSO-d6)δ11.52and11.31(s,1H,NH),11.16and11.05(s,1H,Pyrrole-NH),10.83and10.80(s,1H,O=C-NH),8.15and7.88(s,1H,N=CH),7.45-7.35(m,1H,Ar-H),7.30(d,3JHH=7.2Hz,1H,Ar-H),7.03(t,3JHH=7.2Hz,1H,Ar-H),6.95(t,3JHH=7.2Hz,1H,Ar-H),6.90and6.83(s,1H,Pyrrole-H),6.45and6.39(s,1H,Pyrrole-H),6.13and6.08(s,1H,Pyrrole-H),4.60and3.58(d,3JHH=8.8Hz,1H,CH),4.24-4.08(m,1H,CH),2.98-2.88(m,1H,CH2),2.70-2.59(m,1H,CH2),1.50-1.45(m,3H,CH3);HRMS(ESI)calcd for C18H20N5O[M+H]+322.1662,found322.1668。
(1S,3S)-N’-(噻吩-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-20)
黄色固体,收率76%,熔点139-141℃;1H NMR(400MHz,DMSO-d6)δ11.55and11.39(s,1H,NH),10.90and10.83(s,1H,O=C-NH),8.56and8.24(s,1H,N=CH),7.67and7.54(d,3JHH=4.8Hz,1H,Thiophene-H),7.47-7.35(m,2H,Thiophene-H and Ar-H),7.35-7.28(m,1H,Ar-H),7.14and7.09(t,3JHH=4.4Hz,1H,Thiophene-H),7.04(t,3JHH=7.2Hz,1H,Ar-H),7.00-6.90(m,1H,Ar-H),4.38and3.62(dd,3JHH=8.8Hz,4.0Hz,1H,CH),4.29-4.10(m,1H,CH),3.04-2.89(m,1H,CH2),2.77-2.61(m,1H,CH2),1.54-1.38(m,3H,CH3);HRMS(ESI)calcdfor C18H19N4OS[M+H]+339.1274,found339.1278。
(1S,3S)-N’-(咪唑-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-21)
绿色固体,收率81%,熔点188-190℃;1H NMR(400MHz,DMSO-d6)δ14.10,13.33,12.81and12.57(s,1H,Imidzole-NH),12.93and11.47(s,1H,NH),10.84and10.81(s,1H,O=C-NH),8.45,8.26,7.95and7.44(s,1H,N=CH),7.42-6.88(m,6H,Ar-H and Imidzole-H),4.65,4.50,3.69and3.63(m,1H,CH),4.37and4.17(m,1H,CH),3.03and2.95(d,2JHH=14.0Hz,1H,CH2),2.78-2.56(m,1H,CH2),1.52-1.42(m,3H,CH3);HRMS(ESI)calcd forC17H19N6O[M+H]+323.1615,found323.1620。
(1S,3S)-N’-((E)-丁-2-烯亚基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-22)
黄色固体,收率61%,熔点145-148℃;1H NMR(400MHz,CDCl3)δ10.10and9.63(s,1H,NH),8.23and8.15(s,1H,O=C-NH),7.72and7.37(d,3JHH=8.4Hz,1H,N=CH),7.43(d,3JHH=6.8Hz,1H,Ar-H),7.35-7.27(m,1H,Ar-H),7.20-7.00(m,2H,Ar-H),6.42-5.94(m,2H,CHCH),4.57-4.48and3.70-3.58(m,1H,CH),4.31-4.06(m,1H,CH),3.27and3.12(d,2JHH=14.4Hz,1H,CH2),2.85-2.66(m,1H,CH2),2.09(br,1H,NH),1.92-1.75(m,3H,CH3),1.50and1.43(d,3JHH=5.6Hz,3H,CH3);HRMS(ESI)calcd for C18H20N5O[M+H]+297.1710,found297.1714。
(1S,3S)-N’-亚丁基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-23)
黄色固体0.52g,收率71%,熔点113-117℃;1H NMR(400MHz,DMSO-d6)δ11.04and10.97(s,1H,NH),10.82and10.80(s,1H,O=C-NH),7.59and7.42-7.33(m,2H,N=CH and Ar-H),7.30(d,3JHH=7.6Hz,1H,Ph-H),7.03(t,3JHH=6.8Hz,1H,Ar-H),6.95(t,3JHH=6.8Hz,1H,Ar-H),4.28and3.51(d,3JHH=9.6Hz,1H,CH),4.19-4.04(m,1H,CH),2.89(d,2JHH=14.0Hz,1H,CH2),2.67and2.57(t,2JHH=12.8Hz,1H,CH2),2.25-2.10(m,2H,CH2),1.55-1.40(m,5H,CH3and CH2),0.92and0.86(t,3JHH=6.8Hz,3H,CH3);HRMS(ESI)calcd forC17H23N4O[M+H]+299.1866,found299.1870。
(1S,3S)-N’-亚辛基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-24)
黄色固体,收率78%,熔点68-71℃;1H NMR(400MHz,CDCl3)δ9.94and9.02(s,1H,NH),7.90and7.50(s,1H,N=CH),7.50and7.46(d,3JHH=8.0Hz,1H,Ar-H),7.34and7.32(d,3JHH=8.4Hz,1H,Ar-H),7.17(t,3JHH=7.2Hz,1H,Ar-H),7.11(t,3JHH=7.2Hz,1H,Ar-H),4.53and3.70(dd,3JHH=11.2Hz,4.4Hz,1H,CH),4.33-4.17(m,1H,CH),3.37and3.13(dd,3JHH=2.8Hz,2JHH=14.4Hz,1H,CH2),2.83-2.72(m,1H,CH2),2.38and2.22(q,3JHH=7.2Hz,2H,CH2),1.96(br,1H,NH),1.58-1.43(m,4H,CH2and CH3),1.42-1.18(m,9H,CH2),0.95-0.81(m,3H,CH3);HRMS(ESI)calcd for C21H31N4O[M+H]+355.2493,found355.2492。
(1S,3S)-N’-(环己基亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-25)
黄色固体,收率92%,熔点123-126℃;1H NMR(400MHz,CDCl3)δ9.88and9.21(s,1H,NH),7.98and7.96(s,1H,N=CH),7.49and7.47(d,3JHH=8.0Hz,1H,Ar-H),7.38-7.29and7.05(m,2H,Ar-H and O=C-NH),7.16and7.16(t,3JHH=7.2Hz,1H,Ar-H),7.10(t,3JHH=7.2Hz,1H,Ar-H),4.52and3.66(dd,3JHH=10.8Hz,4.4Hz,1H,CH),4.28and4.18(q,3JHH=6.8Hz,1H,CH),3.35and3.12(dd,3JHH=2.8Hz,2JHH=15.6Hz,1H,CH2),2.85-2.72(m,1H,CH2),2.47-2.35and2.23-2.13(m,1H,CH),1.94(br,1H,NH),1.87-1.58(m,4H,CH2),1.53and1.48(d,3JHH=10.8Hz,3H,CH3),1.38-1.11(m,6H,CH2),0.95-0.81(m,3H,CH3);HRMS(ESI)calcd for C20H27N4O[M+H]+339.2180,found339.2179。
(1S,3S)-N’-(2,2-二甲基亚丙基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-26)
黄色固体,收率95%,熔点140-141℃;1H NMR(100MHz,CDCl3)δ9.93and9.39(s,1H,NH),8.13and8.09(s,1H,N=CH),7.53-7.02(m,4H,Ar-H),4.51and3.67(d,3JHH=8.4Hz,1H,CH),4.37-4.16(m,1H,CH),3.33and3.13(d,2JHH=14.4Hz,1H,CH2),2.79(t,2JHH=13.2Hz,1H,CH2),2.09(br,1H,NH),1.58-1.41(m,3H,CH3),1.15and1.06(s,9H,CH3);HRMS(ESI)calcd for C18H25N4O[M+H]+313.2023,found313.2028。
(1S,3S)-N′-(1-苯基亚乙基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-27)
淡黄色固体,收率56%,熔点221-224℃;1H NMR(400MHz,DMSO-d6)δ10.84and10.81(s,1H,N-H),10.69and10.48(s,1H,O=C-NH),7.89-7.77and7.76-7.67(m,2H,Ph-H),7.48-7.27(m,5H,Ph-H and Ar-H),7.08-6.88(m,2H,Ar-H),4.53and3.78(dd,3JHH=10.8Hz,3.6Hz,1H,CH),4.23-4.11(m,1H,CH),3.03-2.93(m,1H,CH2),2.76-2.59(m,1H,CH2),3.31and3.30(s,3H,CH3),1.46(d,3JHH=6.4Hz,3H,CH3);HRMS(ESI)calcd for C21H23N4O[M+H]+347.1867,found347.1872。
(1S,3S)-N′-(3,3-二甲基丁-2-亚基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-28)
黄色固体,收率63%,熔点103-107℃;1H NMR(400MHz,DMSO-d6)δ10.80and10.79(s,1H,N-H),10.18and10.02(s,1H,O=C-NH),7.40and7.35(d,3JHH=7.6Hz,1H,Ar-H),7.29(d,3JHH=8.0Hz,1H,Ar-H),7.03(t,3JHH=7.2Hz,1H,Ar-H),6.95and6.93(t,3JHH=6.8Hz,1H,Ar-H),4.26and3.65(dd,3JHH=10.8Hz,4.0Hz,1H,CH),4.16-4.07(m,1H,CH),2.94(dd,3JHH=2.8Hz,2JHH=14.8Hz,1H,CH2),2.70-2.53(m,1H,CH2),1.87and1.85(s,3H,CH3),1.43(d,3JHH=6.4Hz,3H,CH3),1.12and1.04(s,9H,CH3);HRMS(ESI)calcd for C19H27N4O[M+H]+327.2180,found327.2186。
(1S,3S)-N′-亚环己基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-29)
黄色固体,收率60%,熔点131-135℃;1H NMR(400MHz,DMSO-d6)δ10.81and10.78(s,1H,NH),10.39and10.24(s,1H,O=C-NH),7.39and7.36(d,3JHH=8.0Hz,1H,Ar-H),7.29(d,3JHH=7.6Hz,1H,Ar-H),7.02(t,3JHH=7.2Hz,1H,Ar-H),6.94(t,3JHH=7.2Hz,1H,Ar-H),4.36and3.62(dd,3JHH=10.0Hz,3.6Hz,1H,CH),4.18-4.04(m,1H,CH),2.94-2.84(m,1H,CH2),2.69-2.58(m,1H,CH2),2.40-2.12(m,4H,CH2),1.71-1.51(m,6H,CH2),1.42(d,3JHH=6.0Hz,3H,CH3);HRMS(ESI)calcd for C19H25N4O[M+H]+325.2023,found325.2023。
实施例20:N′-((1S,3S)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-三甲酸基)苯并[d][1,2,3]噻二唑-7-甲酰肼(Id-1)
100mL单口瓶中加入酰肼0.40g(1.64mmol),40mL四氢呋喃,加入NEt30.22g(2.17mmol),加入酰氯(1.64mmol)的四氢呋喃溶液,滴毕,室温搅拌过夜,脱溶,得绿色固体0.48g,收率72%,熔点180-183℃;1H NMR(400MHz,DMSO-d6)δ11.22(br,1H,O=C-NH),10.91(s,1H,NH),10.37(br,1H,O=C-NH),9.00(d,3JHH=8.0Hz,1H,Ph-H),8.62(d,3JHH=7.2Hz,1H,Ph-H),7.99(t,3JHH=7.6Hz,1H,Ph-H),7.44(d,3JHH=7.6Hz,1H,Ar-H),7.33(d,3JHH=8.0Hz,1H,Ar-H),7.06(t,3JHH=7.2Hz,1H,Ar-H),6.99(t,3JHH=7.2Hz,1H,Ar-H),4.40-4.20(m,1H,CH),3.97-3.76(m,1H,CH),3.11-2.99(m,1H,CH2),2.85-2.73(m,1H,CH2),1.50(d,3JHH=6.0Hz,3H,CH3);HRMS(ESI)calcd for C20H19N6O2S[M+H]+407.1285,found407.1281。
化合物Id-2-Id-7通过重复上述步骤完成
4-甲基-N′-((1S,3S)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰基)-1,2,3-噻二唑-5-甲酰肼(Id-2)
绿色固体,收率56%,熔点145-148℃;1H NMR(400MHz,DMSO-d6)δ10.85(s,1H,NH),10.29(br,1H,O=C-NH),7.40(d,3JHH=7.2Hz,1H,Ar-H),7.31(d,3JHH=7.6Hz,1H,Ar-H),7.04(t,3JHH=6.8Hz,1H,Ar-H),6.97(t,3JHH=6.8Hz,1H,Ar-H),4.25-4.11(m,1H,CH),3.78-3.62(m,1H,CH),3.03-2.92(m,1H,CH2),2.85(s,3H,CH3),2.78-2.64(m,1H,CH2),1.46(d,3JHH=5.2Hz,3H,CH3);HRMS(ESI)calcd for C17H19N6O2S[M+H]+371.1285,found371.1287。
(1S,3S)-N′-异烟酰基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-3)
棕色固体,收率23%,熔点243-245℃;1H NMR(400MHz,DMSO-d6)δ10.81(s,2H,NHand O=C-NH),10.14(br,1H,O=C-NH),8.78(d,3JHH=4.0Hz,2H,Py-H),7.81(d,3JHH=4.0Hz,2H,Py-H),7.39(d,3JHH=7.2Hz,1H,Ar-H),7.30(d,3JHH=7.6Hz,1H,Ar-H),7.04(t,3JHH=7.2Hz,1H,Ar-H),6.96(t,3JHH=7.2Hz,1H,Ar-H),4.18-4.08(m,1H,CH),3.69-3.59(m,1H,CH),2.98-2.88(m,1H,CH2),2.76-2.64(m,1H,CH2),1.44(d,3JHH=6.4Hz,3H,CH3);HRMS(ESI)calcd for C19H20N5O2[M+H]+350.1612,found350.1606。
(1S,3S)-N′-苯甲酰基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-4)
黄色固体,收率93%,熔点140-143℃;1H NMR(400MHz,DMSO-d6)δ10.83(s,1H,NH),10.47(br,1H,O=C-NH),10.02(br,1H,and O=C-NH),7.92(d,3JHH=7.2Hz,2H,Ph-H),7.60(t,3JHH=7.2Hz,1H,Ph-H),7.52(t,3JHH=7.2Hz,2H,Ph-H),7.40(d,3JHH=7.2Hz,1H,Ar-H),7.31(d,3JHH=8.0Hz,1H,Ar-H),7.04(t,3JHH=7.2Hz,1H,Ar-H),6.97(t,3JHH=7.2Hz,1H,Ar-H),4.20-4.11(m,1H,CH),3.66(dd,3JHH=10.0Hz,3.2Hz,1H,CH),2.95(dd,3JHH=2.8Hz,2JHH=14.4Hz,1H,CH2),2.75-2.65(m,1H,CH2),1.45(d,3JHH=6.8Hz,3H,CH3);HRMS(ESI)calcd for C20H21N4O2[M+H]+349.1659,found349.1665。
(1S3S)-N′-正己酰基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-5)
浅黄色固体,收率78%,熔点97-100℃;1H NMR(400MHz,DMSO-d6)δ10.79(s,1H,NH),9.87(s,1H,O=C-NH),9.81(br,1H,O=C-NH),7.37(d,3JHH=7.6Hz,1H,Ar-H),7.29(d,3JHH=8.0Hz,1H,Ar-H),7.03(t,3JHH=7.2Hz,1H,Ar-H),6.95(t,3JHH=7.2Hz,1H,Ar-H),4.15-4.03(m,1H,CH),3.55(dd,3JHH=10.4Hz,3.6Hz,1H,CH),2.87(dd,3JHH=2.4Hz,2JHH=14.8Hz,1H,CH2),2.62(ddd,4JHH=2.0Hz,3JHH=10.8Hz,2JHH=14.8Hz,1H,CH2),2.15(t,3JHH=7.2Hz,2H,CH2),1.60-1.48(m,2H,CH2),1.42(d,3JHH=6.8Hz,3H,CH3),1.34-1.21(m,4H,CH2CH2),0.88(t,3JHH=6.8Hz,2H,CH2);HRMS(ESI)calcd for C19H27N4O2[M+H]+343.2129,found343.2132。
(1S,3S)-N′-特戊酰基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-6)
黄色固体,收率93%,熔点124-126℃;1H NMR(400MHz,CDCl3)δ8.83(br,1H,O=C-NH),8.34(s,1H,O=C-NH),7.25(d,3JHH=7.6Hz,1H,Ar-H),7.15(d,3JHH=7.6Hz,1H,Ar-H),7.00(t,3JHH=7.2Hz,1H,Ar-H),6.93(t,3JHH=7.2Hz,1H,Ar-H),3.95-3.81(m,1H,CH),3.49(dd,3JHH=10.8Hz,8.0Hz,1H,CH),3.05-2.91(m,1H,CH2),2.63-2.50(m,1H,CH2),1.30-1.07(m,12H,CH3);HRMS(ESI)calcd for C18H25N4O2[M+H]+329.1972,found429.1975。
(1S,3S)-N′-(环戊基甲酰基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-7)
白色固体,收率80%,熔点141-144℃;1H NMR(400MHz,DMSO-d6)δ10.83(s,1H,NH),9.94-9.74(m,2H,O=C-NH),7.37(d,3JHH=7.6Hz,1H,Ar-H),7.30(d,3JHH=8.0Hz,1H,Ar-H),7.03(t,3JHH=7.2Hz,1H,Ar-H),6.96(t,3JHH=7.2Hz,1H,Ar-H),4.19-4.06(m,1H,CH),3.66-3.54(m,1H,CH),2.96-2.84(m,1H,CH2),2.72-2.57(m,2H,CH2and cyclopentyl-CH),1.85-1.48(m,8H,cyclopentyl-CH2),1.43(d,3JHH=6.4Hz,3H,CH3);HRMS(ESI)calcd forC19H25N4O2[M+H]+341.1972,found341.1968。
实施例21:抗烟草花叶病毒活性的测定,测定程序如下:
1、病毒提纯及浓度测定:
病毒提纯及浓度测定参照南开大学元素所生测室编制烟草花叶病毒SOP规范执行。病毒粗提液经2次聚乙二醇离心处理后,测定浓度,4℃冷藏备用。
2、化合物溶液配制:
称量后,原药加入DMF溶解,制得1×105μg/mL母液,后用含1‰吐温80水溶液稀释至所需浓度;宁南霉素制剂直接兑水稀释。
3、离体作用:
摩擦接种珊西烟适龄叶片,用流水冲洗,病毒浓度10μg/mL。收干后剪下,沿叶中脉对剖,左右半叶分别浸于1‰吐温水及药剂中,30min后取出,于适宜光照温度下保湿培养,每3片叶为1次重复,重复3次。3d后记录病斑数,计算防效。
4、活体保护作用:
选长势均匀一致的3-5叶期珊西烟,全株喷雾施药,每处理3次重复,并设1‰吐温80水溶液对照。24h后,叶面撤布金刚砂(500目),用毛笔蘸取病毒液,在全叶面沿支脉方向轻擦2次,叶片下方用手掌支撑,病毒浓度10μg/mL,接种后用流水冲洗。3d后记录病斑数,计算防效。
5、活体治疗作用:
选长势均匀一致的3-5叶期珊西烟,用毛笔全叶接种病毒,病毒浓度为10μg/mL,接种后用流水冲洗。叶面收干后,全株喷雾施药,每处理3次重复,并设1‰吐温80水溶液对照。3d后记录病斑数,计算防效。
6、活体钝化作用:
选长势均匀一致的3-5叶期珊西烟,将药剂与等体积的病毒汁液混合钝化30min后,摩擦接种,病毒浓度20μg/mL,接种后即用流水冲洗,重复3次,设1‰吐温80水溶液对照。3d后数病斑数,计算结果。
抑制率(%)=[(对照枯斑数-处理枯斑数)/对照枯斑数]×100%
表1部分β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱及其衍生物(Ia,Ib,Ic和Id)的抗TMV活性测试结果:
从表1中可见,大多数β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱及其衍生物(Ia,Ib,Ic,和Id)表现出很高离体抗TMV活性,而且大部分化合物表现出很好的抗烟草花叶病毒(TMV)活体活性,大部分生物碱以及酰腙类化合物抗烟草花叶病毒活体活性明显优于商品化品种病毒唑,尤其是化合物Harmalan,Tetrahydroharmane,Harmane,Tetrahydroharmine,Ia-1,Ib-8,Ib-13,Ib-15,Ic-1-Ic-9,Ic-12,Ic-19,Ic-20,Ic-24-Ic-26,Ic-28,Id-1,Id-6,Id-7在100μg/mL浓度下抗烟草花叶病毒活性与商品化品种宁南霉素在100μg/mL浓度下的活性相当,具备极大的开发价值。
实施例22:杀真菌活性的测定,测定程序如下:
以番茄早疫病菌为例,可以换成其他菌
离体测试方法:将番茄早疫病菌接到PDA培养基上培养7天,用打孔器在菌落边缘制取直径4cm的菌碟接种到含有50ug/ml和不含药剂的PDA培养基上培养4天,量取菌落直径,与对照比较计算出药剂的抑制百分率。
表2部分β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱及其衍生物(Ia,Ib,Ic和Id)的杀菌活性测试结果:
从表2中可见,大多数β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱及其衍生物(Ia,Ib,Ic和Id)对14种真菌表现出较高的杀菌活性,尤其是化合物Ia-1,Ic-2,Ic-5和Ic-7对多种真菌都表现很好的杀菌活性。
实施例23:杀粘虫、棉铃虫和玉米螟活性的测定,测定程序如下:
棉铃虫的活性测试
棉铃虫的实验方法:饲料混药法,从配置好的溶液中移取3mL加入约27g的刚配置好的饲料中,从而得到稀释十倍的所需浓度。药剂混匀后均匀地倒入干净的24孔板中,晾凉后接入24头三龄棉铃虫,观察3-4天后检查结果。
粘虫的活性测试
粘虫的实验方法:浸叶法,配置后所需浓度后,把直径约为5-6cm的叶片浸入药液中5-6秒,取出,放在吸水纸上晾干,放在指定的培养皿中,接入10头3龄幼虫,放入27±1℃的养虫室中观察3-4天后检查结果。
玉米螟的活性测试
玉米螟的试验方法:浸叶法,配置后所需浓度后,把直径约为5-6cm的叶片浸入药液中5-6秒,取出,放在吸水纸上晾干,放在指定的培养皿中,接入10头3龄幼虫,放入27±1℃的养虫室中观察3-4天后检查结果。
表3部分β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱及其衍生物(Ia,Ib,Ic和Id)的杀粘虫、棉铃虫和玉米螟活性测试结果:
从表3中可见,大多数β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱及其衍生物(Ia,Ib,Ic和Id)对粘虫、棉铃虫和玉米螟均表现出一定活性。尤其是化合物Ia-8,Ib-13,Ib-16,Ib-20,Ic-1,Ic-11和Ic-19表现出广谱活性。
实施例24:杀蚊幼虫活性的测定,测定程序如下:
蚊幼虫的活性测试
蚊幼虫的实验方法:尖音库蚊淡色亚种,室内饲养的正常群体。称取供试化合物约5mg于盘尼西林药瓶中,加5mL丙酮(或适宜溶剂),振荡溶解,即为1000ppm母液。移取0.5mL母液,加入盛有89.9mL水的100mL烧杯中,选取10头4龄初蚊子幼虫,连同10mL饲养液一并倒入烧杯中,其药液的浓度即为5ppm。放入标准处理室内,24h检查结果。以含有0.5mL试验溶剂的水溶液为空白对照。
表4部分β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱及其衍生物(Ia,Ib,Ic和Id)的杀蚊幼虫活性测试结果:
从表4中可见,大多数β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱及其衍生物(Ia,Ib,Ic和Id)对尖音库蚊的幼虫表现出较高的活性,其中Ia-3,Ia-8,Ib-13,Ib-16,Ic-1和Ic-19在5mg/kg下仍表现出较高活性。

Claims (12)

1.如下通式(I)所示结构的β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物
其中,
R代表氢、一个至四个卤素原子、一个至四个硝基、一个至四个氰基、一个至四个1-6碳烷氧基、一个至四个羟基、一个至两个-OCH2O-、一个至两个-OCH2CH2O-、一个至四个1-6碳烷羰基、一个至四个1-10碳烷氧羰基、一个至四个1-10碳烷胺羰基、一个至四个1-6碳烷氧羰氧基、一个至四个1-6碳烷胺羰氧基、一个至四个1-10碳α-胺基烷羰氧基;
R1分别代表羟基、卤素原子、氰基、1-10碳烃基、1-6碳烷氧基、1-4碳烷基羰氧基、1-4碳烷氧基羰氧基、1-10碳含氮杂环、1-10碳含氧杂环、1-10碳含硫杂环;
R2分别代表羟基、1-6碳烷氧基、卤素原子、氰基、1-6碳烷羰基、1-10碳烷氧羰基、1-10碳烷胺羰基、1-6碳烷氧羰氧基、1-6碳烷胺羰氧基;
以及上述化合物的立体异构体;
以上化合物不包括1-甲基-β-咔啉-3-甲酸甲酯、1-甲基-β-咔啉-3-甲醛、(1S,3S)-1-乙基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酸乙酯。
2.如下通式(Ic)、(Id)所示结构的四氢-β-咔啉生物碱衍生物
其中,R4和R5分别代表氢、1-10碳烃基、1-10碳含氮杂环、1-10碳含氧杂环、1-10碳含硫杂环;R4和R5为1-10碳脂肪环、1-10碳不饱和碳环、1-10碳含氮杂环、1-10碳含氧杂环、1-10碳含硫杂环;R6分别代表氢、羟基、氨基、1-10碳烃基、1-6碳烷氧基、1-10碳含氮杂环、1-10碳含氧杂环、1-10碳含硫杂环。
3.β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物,其特征在于所述化合物是:
(E)-3-(1-甲基-吡啶并[3,4-b]吲哚-3)-丙烯酸(Ia-14);
(E)-3-(1-(噻吩-2)-吡啶并[3,4-b]吲哚-3)-丙烯酸(Ia-15);
(E)-3-(1-(吡啶-3)-吡啶并[3,4-b]吲哚-3)-丙烯酸(Ia-16);
(1S,3S)-N-丁基-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-16);
(1S,3S)-N-环己基-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-17);
(1S,3S)-N-(2-羟乙基)-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-18);
(1S,3S)-N-(二甲氨基甲基)-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-19);
(1S,3S)-N-((四氢呋喃-2)-甲基)-1-甲基-2,3,4,9-四氢-吡啶并[3,4-b]吲哚-3-甲酰胺(Ib-20);
(1S,3S)-N′-苯亚甲基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-1);
(1S,3S)-N′-(4-叔丁基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-2);
(1S,3S)-N′-(4-二甲氨基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-3);
(1S,3S)-N′-(4-硝基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-4);
(1S,3S)-N′-(4-氯苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-5);
(1S,3S)-N′-(2,4-二氯苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-6);
(1S,3S)-N′-(3,4-二氯苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-7);
(1S,3S)-N′-(4-甲氧基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-8);
(1S,3S)-N′-(3-甲氧基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-9);
(1S,3S)-N′-(2-甲氧基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-10);
(1S,3S)-N′-(3,4-二甲氧基苯亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-11);
(1S,3S)-N′-((苯并[d][1,3]二氧亚甲基-5)-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-12);
(1S,3S)-N′-((2,3-二氢苯并[b][1,4]二氧芑-6-亚甲基)-1-甲基)-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-13);
(1S,3S)-N′-(6-羟基萘-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-14);
(1S,3S)-N′-(吡啶-4-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-15);
(1S,3S)-N′-(吡啶-3-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-16);
(1S,3S)-N′-(吡啶-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-17);
(1S,3S)-N′-(呋喃-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-18);
(1S,3S)-N′-(吡咯-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-19);
(1S,3S)-N′-(噻吩-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-20);
(1S,3S)-N′-(咪唑-2-亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-21);
(1S,3S)-N′-((E)-丁-2-烯亚基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-22);
(1S,3S)-N′-亚丁基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-23);
(1S,3S)-N′-亚辛基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-24);
(1S,3S)-N′-(环己基亚甲基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-25);
(1S,3S)-N′-(2,2-二甲基亚丙基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-26);
(1S,3S)-N′-(1-苯基亚乙基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-27);
(1S,3S)-N′-(3,3-二甲基丁-2-亚基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-28);
(1S,3S)-N′-亚环己基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Ic-29);
N′-((1S,3S)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-三甲酸基)苯并[d][1,2,3]噻二唑-7-甲酰肼(Id-1);
4-甲基-N′-((1S,3S)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰基)-1,2,3-噻二唑-5-甲酰肼(Id-2);
(1S,3S)-N′-异烟酰基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-3);
(1S,3S)-N′-苯甲酰基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-4);
(1S,3S)-N′-正己酰基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-5);
(1S,3S)-N′-特戊酰基-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-6);
(1S,3S)-N′-(环戊基甲酰基)-1-甲基-2,3,4,9-四氢吡啶并[3,4-b]吲哚-3-甲酰肼(Id-7)。
4.一种制备β-咔啉生物碱衍生物的方法(路线七):首先,L-色氨酸与乙醛水溶液反应得环化产物Ib-1,然后经过一步酯化得化合物Ib-13,该化合物经过脱氢氧化得化合物Ia-10,化合物Ia-10碱性条件下水解得化合物Ia-11,化合物Ia-10经过四氢铝锂还原得化合物Ia-12,该化合物经过氧化得醛Ia-13,化合物Ia-13与丙二酸反应得丙烯酸Ia-14,路线七:
5.一种制备二氢-β-咔啉生物碱衍生物的方法(路线九):L-色氨酸与乙醇反应得乙酯6,6经过酰化后再与三氯氧磷反应得二氢-β-咔啉生物碱衍生物Ib-14,路线九:
6.一种制备四氢-β-咔啉生物碱衍生物的方法(路线十):甲酯Ib-7与80%水合肼水溶液反应得化合物Ib-15,化合物Ib-7与胺反应得到酰胺Ib-16和Ib-18,路线十:
7.一种制备四氢-β-咔啉生物碱衍生物的方法(路线十一):酸Ib-1在缩合试剂的作用下与胺反应得酰胺Ib-17,Ib-19-Ib-20,路线十一:
8.一种制备四氢-β-咔啉生物碱衍生物的方法(路线十二):酰肼化合物Ib-15与脂肪醛或芳香醛反应得到相应的酰腙类化合物Ic-1-Ic-29,路线十二:
R4=氢R5=苯基,4-叔丁基苯基,4-二甲氨基苯基,4-硝基苯基,4-氯苯基,
2,4-二氯苯基,3,4-二氯苯基,4-甲氧基苯基,3-甲氧基苯基,
2-甲氧基苯基,3,4-二甲氧基苯基,苯并[d][1,3]二氧杂环戊-5-基,
2,3-二氢苯并[b][1,4]二氧杂芑-6-基,6-羟基-2-萘基,4-吡啶基,3-吡啶基,
2-吡啶基,2-呋喃基,2-咪唑基,(E)-2-丁烯基,正丁基,正辛基,环己基,叔丁基:
或R4=甲基R5=苯基,叔丁基,环己基。
9.一种制备四氢-β-咔啉生物碱衍生物的方法(路线十三):酰肼化合物Ib-15与酰氯反应得到相应的双酰肼类化合物Id-1-Id-7,路线十三:
R6=苯并[d][1,2,3]噻二唑-7-基,4-甲基-1,2,3-噻二唑-5-基,4-吡啶基,苯基,正戊基,叔丁基,环戊基。
10.按照权利要求1至3中任意一项所述的β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物在防治植物病毒方面的应用,其特征在于所述植物病毒为烟草花叶病毒、辣椒病毒、水稻病毒、番茄病毒、甘薯病毒、马铃薯病毒和瓜类病毒及玉米矮花叶病毒。
11.按照权利要求1至3中任意一项所述的β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物在杀病原菌方面的应用,其特征在于所述病原菌为黄瓜枯萎、花生褐斑、苹果轮纹、番茄早疫、小麦赤霉、马铃薯晚疫、油菜菌核、黄瓜灰霉、水稻纹枯、辣椒疫霉、水稻恶苗、小麦纹枯、玉米小斑和西瓜炭疽。
12.按照权利要求1至3中任意一项所述的β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物在杀害虫方面的应用,其特征在于所述害虫为粘虫、棉铃虫、玉米螟和尖音库蚊。
CN201310752240.2A 2013-12-30 2013-12-30 β‑咔啉,二氢‑β‑咔啉和四氢‑β‑咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用 Active CN104744460B (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN201310752240.2A CN104744460B (zh) 2013-12-30 2013-12-30 β‑咔啉,二氢‑β‑咔啉和四氢‑β‑咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
EP14876613.2A EP3091015B1 (en) 2013-12-30 2014-12-24 Beta-carboline, dihydro-beta-carboline and tetrahydro-beta-carboline alkaloid derivatives and method for preparing same and use in aspects of preventing and treating plant viruses, fungicides and insecticides
EP18203967.7A EP3459951B1 (en) 2013-12-30 2014-12-24 Tetrahydro-beta-carboline alkaloid derivatives, method for preparing the same and use in aspects of preventing and treating plant viruses, as fungicides and insecticides
PCT/CN2014/094847 WO2015101206A1 (zh) 2013-12-30 2014-12-24 β-咔啉,二氢-β-咔啉和四氢-β-咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
EP18203964.4A EP3459950B1 (en) 2013-12-30 2014-12-24 Tetrahydro-beta-carboline alkaloid derivatives, method for preparing the same and use in aspects of preventing and treating plant viruses, as fungicides and insecticides
US15/109,371 US10208033B2 (en) 2013-12-30 2014-12-24 β-carboline, dihydro-β-carboline and tetrahydro-β-carboline alkaloid derivatives and preparation methods same and use in aspects of preventing and treating plant viruses, fungicides and insecticides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310752240.2A CN104744460B (zh) 2013-12-30 2013-12-30 β‑咔啉,二氢‑β‑咔啉和四氢‑β‑咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用

Publications (2)

Publication Number Publication Date
CN104744460A CN104744460A (zh) 2015-07-01
CN104744460B true CN104744460B (zh) 2017-06-16

Family

ID=53493203

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310752240.2A Active CN104744460B (zh) 2013-12-30 2013-12-30 β‑咔啉,二氢‑β‑咔啉和四氢‑β‑咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用

Country Status (4)

Country Link
US (1) US10208033B2 (zh)
EP (3) EP3459950B1 (zh)
CN (1) CN104744460B (zh)
WO (1) WO2015101206A1 (zh)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
CN105481855B (zh) * 2015-12-22 2018-02-06 西北农林科技大学 β‑咔啉类化合物及其合成方法、以及含有该化合物的药物及应用
CN105859713B (zh) * 2016-04-29 2017-08-08 华南农业大学 一种骆驼蓬碱噁唑啉类衍生物及其制备方法和应用
CN107652296B (zh) * 2016-07-26 2020-08-04 南开大学 螺环氧化吲哚酰腙衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
CN107056779B (zh) * 2017-04-25 2019-03-12 三峡大学 一种希夫碱荧光探针qcs及其制备方法
CN107417685B (zh) * 2017-08-18 2019-12-31 西华大学 非对应选择性合成1-芳基-1H-吡啶[3,4-b]吲哚衍生物
CN107568240A (zh) * 2017-09-30 2018-01-12 京博农化科技股份有限公司 一种含盐酸吗啉胍的抗植物病毒组合物
CN107711856A (zh) * 2017-09-30 2018-02-23 京博农化科技股份有限公司 一种含苦参碱的组合物
CN107568233A (zh) * 2017-09-30 2018-01-12 京博农化科技股份有限公司 一种含有氨基寡糖素的杀菌组合物
CN107637604A (zh) * 2017-09-30 2018-01-30 京博农化科技股份有限公司 一种作物抗病毒组合物
CN107549181A (zh) * 2017-09-30 2018-01-09 京博农化科技股份有限公司 一种含宁南霉素的组合物
CN107711833A (zh) * 2017-09-30 2018-02-23 京博农化科技股份有限公司 一种含辛菌胺的抗病毒组合物
CN107624771A (zh) * 2017-09-30 2018-01-26 京博农化科技股份有限公司 一种含极细链格孢激活蛋白的杀菌组合物
CN107593732A (zh) * 2017-09-30 2018-01-19 京博农化科技股份有限公司 一种含宁南霉素的防治植物病毒病组合物
CN107637603A (zh) * 2017-09-30 2018-01-30 京博农化科技股份有限公司 一种含丁子香酚的抗病毒组合物
CN107646860A (zh) * 2017-09-30 2018-02-02 京博农化科技股份有限公司 一种含香菇多糖的抗植物病毒病组合物
CN107801722A (zh) * 2017-09-30 2018-03-16 京博农化科技股份有限公司 一种抗病毒组合物
CN107549182A (zh) * 2017-09-30 2018-01-09 京博农化科技股份有限公司 一种含有葡聚烯糖的抗病毒组合物
CN107568234A (zh) * 2017-09-30 2018-01-12 京博农化科技股份有限公司 一种抗病毒组合物
CN107624770A (zh) * 2017-09-30 2018-01-26 京博农化科技股份有限公司 一种含甲噻诱胺的组合物
CN107801723A (zh) * 2017-09-30 2018-03-16 京博农化科技股份有限公司 防治植物病毒病的农药组合物及其应用
CN110759896B (zh) * 2018-07-26 2022-12-13 南开大学 哌嗪二酮酰腙衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
CN110759911B (zh) * 2018-07-26 2022-05-24 南开大学 咔啉衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
CN109757497A (zh) * 2018-12-28 2019-05-17 京博农化科技有限公司 一种杀菌组合物
CN109984133A (zh) * 2019-04-03 2019-07-09 江西鑫邦科技有限责任公司 一种含有芸苔素内酯类化合物的防治病毒病的农药组合物
CN111825670A (zh) * 2019-04-22 2020-10-27 复旦大学 四氢咔啉衍生物及其制备方法和在制备抗高血压的药物中的用途
CN109997865A (zh) * 2019-04-29 2019-07-12 西华大学 一种含苯醚甲环唑的增效杀菌组合物及应用
CN112174953B (zh) * 2019-07-01 2022-03-29 南京农业大学 新型β-咔啉-噁唑啉类多功能配体β1CarOx及其制备和应用
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
CN110452234B (zh) * 2019-08-29 2022-09-23 贵州大学 一种含三氟甲基吡啶二甲酰胺的席夫碱的衍生物及其应用
CN111303148B (zh) * 2020-02-13 2022-08-30 南京农业大学 一类1-取代β-咔啉衍生物及其应用
WO2021209689A1 (en) * 2020-04-17 2021-10-21 Helsingin Yliopisto Compounds and compositions for treating sweet potato against sweet potato pathogenic viruses
CN111393438B (zh) * 2020-05-21 2021-11-30 石河子大学 一种6-取代-β-咔啉碱类化合物及衍生物的制备方法、应用
CN111961051A (zh) * 2020-09-01 2020-11-20 成都大学 一种杂环胺风险物质1-甲基-9H-吡啶[2,3-b]吲哚的合成方法
CN112021326A (zh) * 2020-09-08 2020-12-04 京博农化科技有限公司 一种含氯吲哚酰肼和农用链霉素的杀菌组合物及其应用
CN112142734B (zh) * 2020-10-15 2022-05-31 京博农化科技有限公司 一种β咔啉类化合物中间体的制备方法及其应用
CN112806383A (zh) * 2021-01-14 2021-05-18 京博农化科技有限公司 一种含毒氟磷的防治大田作物植物病毒病组合物
CN112741104A (zh) * 2021-01-14 2021-05-04 京博农化科技有限公司 一种含毒氟磷的防治植物病毒病组合物
FI130627B (en) 2021-03-31 2023-12-18 Equinorm Ltd NEW HETEROCYCLIC COMPOUNDS AND THEIR USE
CN113307806B (zh) * 2021-05-22 2024-05-14 南京医科大学 β-咔啉类选择性单胺氧化酶B抑制剂及其药物用途
CN115466313A (zh) * 2021-06-10 2022-12-13 首都医科大学 1-咪唑-β-咔啉-3-甲酰-LDV及制备,抗癌转移活性和应用
CN114057738A (zh) * 2021-12-14 2022-02-18 京博农化科技有限公司 一种氯吲哚酰肼的合成方法
CN114478525B (zh) * 2022-03-28 2023-05-30 山东京博农化科技股份有限公司 一种四氢-β-咔啉吡唑酰胺衍生物及其制备方法和应用
CN117050077A (zh) * 2022-05-06 2023-11-14 山东京博农化科技股份有限公司 氯吲哚酰肼的多晶型物及其制备方法和制剂加工工艺
CN115677693A (zh) * 2022-11-18 2023-02-03 江苏医药职业学院 一种四氢-β-咔啉衍生物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037658A1 (en) 1996-04-04 1997-10-16 F.Hoffmann-La Roche Ag Use of derivatives of tetrahydro-beta-carbolines as antimetastatic agents
CN1160352C (zh) * 2001-12-19 2004-08-04 北京大学 具有抗HIV和抗癌活性的3-位取代的β-咔啉化合物,制备方法及其组合物和用途
CN100503607C (zh) 2003-06-02 2009-06-24 新疆华世丹药物研究有限责任公司 去氢骆驼蓬碱衍生物类化合物及其应用
CN100494195C (zh) * 2004-09-03 2009-06-03 首都医科大学 咔啉羧酸衍生物、其合成方法及其用途
CN101020688A (zh) 2007-03-12 2007-08-22 复旦大学 1-(3-吲哚基)-1,2,3,4-四氢-β-咔啉衍生物、制备方法和用途
CN102234277B (zh) * 2010-05-07 2012-12-26 首都医科大学 氨基酸修饰的1-甲基-1,2,3,4-四氢-β-咔啉-3-羧酸及其合成方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
1H-Pyrido[3,4-b]indole-3-carboxylic acid, 1-ethyl-2,3,4,9-tetrahydro-,;CAPLUS;《ACS on STN》;20060324;第1页 *
Synthesis of some Fused β-Carbolines Including the First Example of the Pyrrolo[3,2-c]-β-carboline System;Glenn C. Condie etal;《J. Heterocyclic Chem.》;20010831;第41卷;第532页Scheme 1 *

Also Published As

Publication number Publication date
WO2015101206A1 (zh) 2015-07-09
EP3459951A1 (en) 2019-03-27
US10208033B2 (en) 2019-02-19
EP3459950B1 (en) 2022-05-18
EP3091015A1 (en) 2016-11-09
EP3459950A1 (en) 2019-03-27
EP3459951B1 (en) 2022-05-11
US20160326166A1 (en) 2016-11-10
EP3091015A4 (en) 2017-02-15
EP3091015B1 (en) 2019-02-13
CN104744460A (zh) 2015-07-01

Similar Documents

Publication Publication Date Title
CN104744460B (zh) β‑咔啉,二氢‑β‑咔啉和四氢‑β‑咔啉生物碱衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
CN107652296B (zh) 螺环氧化吲哚酰腙衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
CN109232469A (zh) 一类三取代噻唑酰胺衍生物及其制备方法和用途
CA2873108A1 (en) Plant growth regulating compounds
CN113278020B (zh) 含酰基硫脲结构的pityriacitrin生物碱衍生物及其制备方法和用途
CN105884674B (zh) 色氨酸衍生物及制备方法和在防治植物病毒、杀菌、杀虫方面的应用
CN109516978B (zh) 芦竹碱衍生物及其制备方法和用途
CN108727367A (zh) 含吡啶并嘧啶二酮的苯并噁嗪酮类化合物及其制备方法和应用和除草剂组合物
CN114369082B (zh) 吡啶取代螺环类化合物及其在制备抗植物病毒剂中的应用
CN110759911B (zh) 咔啉衍生物及其制备方法和在防治植物病毒、杀菌、杀虫方面的应用
CN114041471B (zh) 脱氢蟾蜍色胺的用途
CN109666031A (zh) 一种螺环吲哚啉酮类化合物及其制备方法与应用
CN113045474B (zh) 生物碱arundine及其衍生物在防治植物病毒病菌病中的应用
CN110483405B (zh) Kealiinine类衍生物及其制备和在抗植物病毒和病菌中的应用
CN115806555B (zh) Indoloazepinone衍生物及其制备和在防治植物病毒、杀虫、杀菌的应用
CN107814790B (zh) Topsentin类衍生物及其制备和在抗植物病毒和病菌中的应用
CN114805358B (zh) Glyantrypine家族生物碱衍生物及其制备和在防治植物病毒病菌病中的应用
CN113444087B (zh) 含酰腙结构的pityriacitrin生物碱衍生物及其制备方法和用途
CN110759892B (zh) Meridianin类衍生物及其制备和在防治植物病毒病菌病中的应用
CN115246834B (zh) Aldisin衍生物及其制备和在防治植物病毒、杀虫、杀菌方面的应用
CN114044742B (zh) 手性伯胺丙二酰胺化合物及其制备方法和用途
CN115433176B (zh) 含硫脲结构的almazole D生物碱衍生物及其制备方法和用途
CN110679602B (zh) 生物碱essramycin及其衍生物在抗植物病毒中的应用
CN115246835B (zh) 含腙结构的Aldisin衍生物及其制备和应用
CN115611893B (zh) 脱氢蟾蜍色胺衍生物及其制备方法和农业用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20150701

Assignee: JINGBO AGROCHEMICALS TECHNOLOGY Co.,Ltd.

Assignor: NANKAI University

Contract record no.: X2022370000005

Denomination of invention: b- Carboline, dihydrogen- b- Carboline and tetrahydro- b- Carboline alkaloid derivative, its preparation method and its application in plant virus control, sterilization and insecticidal

Granted publication date: 20170616

License type: Exclusive License

Record date: 20220516

EE01 Entry into force of recordation of patent licensing contract